TY  - JOUR
AU  - Draganov, Ivana
AU  - Drndarević, Aneta
AU  - Kovačević, Milena
AU  - Miljković, Branislava
AU  - Vuksanović, Miljanka
AU  - Janković, Aleksandar
AU  - Kalaba, Ana
AU  - Vezmar-Kovačević, Sandra
PY  - 2024
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5604
AB  - Drug-related hospitalizations pose a significant burden to the health-care system. The aim
was to investigate the prevalence of drug-related problems (DRPs) and their association with hospital
admissions in five internal medicine wards. The study included patients admitted to the nephrology,
cardiology, gastroenterology, endocrinology, and geriatric wards. The Pharmaceutical Care Network
Europe classification V9.1 was used for identifying DRPs. In total, 535 patients participated in the study.
We identified 954 DRPs (range 1-7) in 80.7% of patients. Most DRPs were identified on the endocrinology,
cardiology, and geriatric wards, and they were associated with the efficacy of treatment (71.4%), adverse
drug events (10.2%), and unnecessary drug treatment (18.4%). DRPs were associated with the cause of
hospitalization in 74.4% of patients on the nephrology ward, 60.1% and 60.6% of patients on the cardiology
and endocrinology wards, respectively, whereas this number was lower on the geriatric and gastroenterology
wards (26.9% and 8.9%, respectively). Suboptimal drug treatment due to medication omissions was often
associated with the potential cause of hospital admission. Focusing on patients with specific diseases and
DRPs, rather than reducing the number of medications in primary care, may be potentially rational in an
attempt to reduce drug-related hospitalizations.
PB  - Polish Pharmaceutical Society
T2  - Acta Poloniae Pharmaceutica - Drug Research
T1  - Drug-Related Problems Prior to Hospitalization on Internal Medicine Wards
VL  - 81
IS  - 1
SP  - 145
EP  - 154
DO  - 10.32383/appdr/182840
ER  - 

@article{
author = "Draganov, Ivana and Drndarević, Aneta and Kovačević, Milena and Miljković, Branislava and Vuksanović, Miljanka and Janković, Aleksandar and Kalaba, Ana and Vezmar-Kovačević, Sandra",
year = "2024",
abstract = "Drug-related hospitalizations pose a significant burden to the health-care system. The aim
was to investigate the prevalence of drug-related problems (DRPs) and their association with hospital
admissions in five internal medicine wards. The study included patients admitted to the nephrology,
cardiology, gastroenterology, endocrinology, and geriatric wards. The Pharmaceutical Care Network
Europe classification V9.1 was used for identifying DRPs. In total, 535 patients participated in the study.
We identified 954 DRPs (range 1-7) in 80.7% of patients. Most DRPs were identified on the endocrinology,
cardiology, and geriatric wards, and they were associated with the efficacy of treatment (71.4%), adverse
drug events (10.2%), and unnecessary drug treatment (18.4%). DRPs were associated with the cause of
hospitalization in 74.4% of patients on the nephrology ward, 60.1% and 60.6% of patients on the cardiology
and endocrinology wards, respectively, whereas this number was lower on the geriatric and gastroenterology
wards (26.9% and 8.9%, respectively). Suboptimal drug treatment due to medication omissions was often
associated with the potential cause of hospital admission. Focusing on patients with specific diseases and
DRPs, rather than reducing the number of medications in primary care, may be potentially rational in an
attempt to reduce drug-related hospitalizations.",
publisher = "Polish Pharmaceutical Society",
journal = "Acta Poloniae Pharmaceutica - Drug Research",
title = "Drug-Related Problems Prior to Hospitalization on Internal Medicine Wards",
volume = "81",
number = "1",
pages = "145-154",
doi = "10.32383/appdr/182840"
}

Draganov, I., Drndarević, A., Kovačević, M., Miljković, B., Vuksanović, M., Janković, A., Kalaba, A.,& Vezmar-Kovačević, S.. (2024). Drug-Related Problems Prior to Hospitalization on Internal Medicine Wards. in Acta Poloniae Pharmaceutica - Drug Research
Polish Pharmaceutical Society., 81(1), 145-154.
https://doi.org/10.32383/appdr/182840

Draganov I, Drndarević A, Kovačević M, Miljković B, Vuksanović M, Janković A, Kalaba A, Vezmar-Kovačević S. Drug-Related Problems Prior to Hospitalization on Internal Medicine Wards. in Acta Poloniae Pharmaceutica - Drug Research. 2024;81(1):145-154.
doi:10.32383/appdr/182840 .

Draganov, Ivana, Drndarević, Aneta, Kovačević, Milena, Miljković, Branislava, Vuksanović, Miljanka, Janković, Aleksandar, Kalaba, Ana, Vezmar-Kovačević, Sandra, "Drug-Related Problems Prior to Hospitalization on Internal Medicine Wards" in Acta Poloniae Pharmaceutica - Drug Research, 81, no. 1 (2024):145-154,
https://doi.org/10.32383/appdr/182840 . .

TY  - JOUR
AU  - Petrović, Sanja
AU  - Kovačević, Milena
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
PY  - 2024
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5597
AB  - Background: We aimed to characterize newer antiseizure medications (ASMs)-induced hepatotoxicity
in children and identify signals of disproportionate reporting of hepatotoxicity-related adverse drug
events (ADEs).
Research Design and Methods: Case reports reported to VigiBase were accessed using Empirica™
Signal software. To summarize characteristics of the retrieved cases, descriptive statistics were used.
A disproportionality analysis was conducted using the Multi-item Gamma Poisson Shrinker algorithm,
which calculates Empirical Bayesian Geometric Mean value and its lower and upper 95% confidence
limits (EB05 and EB95, respectively). EB05 > 2, N > 0 was considered a signal.
Results: Based on 870 analyzed cases, a higher proportion of cases was reported in girls than in boys
and in patients aged 2–11 years than in other age groups. Most cases were serious. In 25 cases,
hepatotoxicity resulted in death. A high proportion of patients (n = 275, 31.61%) experienced hyper-
sensitivity reactions, mostly due to lamotrigine. The disproportionality analysis yielded 17 signals
concerning felbamate, lamotrigine, levetiracetam, oxcarbazepine, stiripentol, and topiramate. Four
signals were for severe liver injury and concerned felbamate, lamotrigine, levetiracetam, and topira-
mate. Gender-biased reporting frequency was detected for four ASM-ADE combinations.
Conclusion: Our results should serve to raise clinicians’ awareness about the potential association
between several newer ASMs and drug-induced liver injury in children.
PB  - Taylor & Francis
T2  - Expert Opinion on Drug Metabolism & Toxicology
T1  - Hepatotoxicity of newer antiseizure medications in children: an overview and disproportionality analysis of VigiBase
VL  - 20
IS  - 3
SP  - 165
EP  - 173
DO  - 10.1080/17425255.2024.2322114
ER  - 

@article{
author = "Petrović, Sanja and Kovačević, Milena and Vezmar-Kovačević, Sandra and Miljković, Branislava",
year = "2024",
abstract = "Background: We aimed to characterize newer antiseizure medications (ASMs)-induced hepatotoxicity
in children and identify signals of disproportionate reporting of hepatotoxicity-related adverse drug
events (ADEs).
Research Design and Methods: Case reports reported to VigiBase were accessed using Empirica™
Signal software. To summarize characteristics of the retrieved cases, descriptive statistics were used.
A disproportionality analysis was conducted using the Multi-item Gamma Poisson Shrinker algorithm,
which calculates Empirical Bayesian Geometric Mean value and its lower and upper 95% confidence
limits (EB05 and EB95, respectively). EB05 > 2, N > 0 was considered a signal.
Results: Based on 870 analyzed cases, a higher proportion of cases was reported in girls than in boys
and in patients aged 2–11 years than in other age groups. Most cases were serious. In 25 cases,
hepatotoxicity resulted in death. A high proportion of patients (n = 275, 31.61%) experienced hyper-
sensitivity reactions, mostly due to lamotrigine. The disproportionality analysis yielded 17 signals
concerning felbamate, lamotrigine, levetiracetam, oxcarbazepine, stiripentol, and topiramate. Four
signals were for severe liver injury and concerned felbamate, lamotrigine, levetiracetam, and topira-
mate. Gender-biased reporting frequency was detected for four ASM-ADE combinations.
Conclusion: Our results should serve to raise clinicians’ awareness about the potential association
between several newer ASMs and drug-induced liver injury in children.",
publisher = "Taylor & Francis",
journal = "Expert Opinion on Drug Metabolism & Toxicology",
title = "Hepatotoxicity of newer antiseizure medications in children: an overview and disproportionality analysis of VigiBase",
volume = "20",
number = "3",
pages = "165-173",
doi = "10.1080/17425255.2024.2322114"
}

Petrović, S., Kovačević, M., Vezmar-Kovačević, S.,& Miljković, B.. (2024). Hepatotoxicity of newer antiseizure medications in children: an overview and disproportionality analysis of VigiBase. in Expert Opinion on Drug Metabolism & Toxicology
Taylor & Francis., 20(3), 165-173.
https://doi.org/10.1080/17425255.2024.2322114

Petrović S, Kovačević M, Vezmar-Kovačević S, Miljković B. Hepatotoxicity of newer antiseizure medications in children: an overview and disproportionality analysis of VigiBase. in Expert Opinion on Drug Metabolism & Toxicology. 2024;20(3):165-173.
doi:10.1080/17425255.2024.2322114 .

Petrović, Sanja, Kovačević, Milena, Vezmar-Kovačević, Sandra, Miljković, Branislava, "Hepatotoxicity of newer antiseizure medications in children: an overview and disproportionality analysis of VigiBase" in Expert Opinion on Drug Metabolism & Toxicology, 20, no. 3 (2024):165-173,
https://doi.org/10.1080/17425255.2024.2322114 . .

TY  - JOUR
AU  - Perić, Aleksandar
AU  - Gaćeša, Dejan
AU  - Vezmar-Kovačević, Sandra
AU  - Perić, Aneta V.
AU  - Vojvodić, Danilo
AU  - Georgiou, Stella
AU  - Protopapadakis, Evdokia
AU  - Alevizopoulos, Konstantinos
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5346
AB  - Objective. To investigate epidermal growth factor (EGF), transforming growth factor (TGF)- a and interleukin (IL)-8 production in nasal mucosa irrigated with hypertonic 2.3% solution with algae extracts, in comparison to 0.9% NaCl during the first two weeks after surgery for nasal polyposis (NP), in relation to symptoms and local findings. Methods. This prospective study included 20 NP patients postoperatively irrigated with hypertonic and 20 with isotonic solution. We evaluated symptoms (NSS), endoscopic findings (ES) and mediator levels in nasal secretions before and after irrigation. Results. Following treatment, NSS and ES were significantly lower in the hypertonic solution group (p = 0.023; p < 0.001, respectively). The increase in the EGF and the decrease in the TGF-a and IL-8 concentration were higher in the hypertonic group (p < 0.001 for all mediators). Conclusion. Irrigation with a hypertonic solution was found to be more effective than an isotonic solution in nasal mucosa reparation.
PB  - Cambridge University Press
T2  - Journal of Laryngology and Otology
T1  - The effect of nasal douching by hypertonic 2.3% sea water with algae extracts on the concentration of epidermal growth factor, transforming growth factor-α and interleukin-8 in nasal secretions of patients with nasal polyposis following endoscopic surgical treatment
DO  - 10.1017/S0022215123001974
ER  - 

@article{
author = "Perić, Aleksandar and Gaćeša, Dejan and Vezmar-Kovačević, Sandra and Perić, Aneta V. and Vojvodić, Danilo and Georgiou, Stella and Protopapadakis, Evdokia and Alevizopoulos, Konstantinos",
year = "2023",
abstract = "Objective. To investigate epidermal growth factor (EGF), transforming growth factor (TGF)- a and interleukin (IL)-8 production in nasal mucosa irrigated with hypertonic 2.3% solution with algae extracts, in comparison to 0.9% NaCl during the first two weeks after surgery for nasal polyposis (NP), in relation to symptoms and local findings. Methods. This prospective study included 20 NP patients postoperatively irrigated with hypertonic and 20 with isotonic solution. We evaluated symptoms (NSS), endoscopic findings (ES) and mediator levels in nasal secretions before and after irrigation. Results. Following treatment, NSS and ES were significantly lower in the hypertonic solution group (p = 0.023; p < 0.001, respectively). The increase in the EGF and the decrease in the TGF-a and IL-8 concentration were higher in the hypertonic group (p < 0.001 for all mediators). Conclusion. Irrigation with a hypertonic solution was found to be more effective than an isotonic solution in nasal mucosa reparation.",
publisher = "Cambridge University Press",
journal = "Journal of Laryngology and Otology",
title = "The effect of nasal douching by hypertonic 2.3% sea water with algae extracts on the concentration of epidermal growth factor, transforming growth factor-α and interleukin-8 in nasal secretions of patients with nasal polyposis following endoscopic surgical treatment",
doi = "10.1017/S0022215123001974"
}

Perić, A., Gaćeša, D., Vezmar-Kovačević, S., Perić, A. V., Vojvodić, D., Georgiou, S., Protopapadakis, E.,& Alevizopoulos, K.. (2023). The effect of nasal douching by hypertonic 2.3% sea water with algae extracts on the concentration of epidermal growth factor, transforming growth factor-α and interleukin-8 in nasal secretions of patients with nasal polyposis following endoscopic surgical treatment. in Journal of Laryngology and Otology
Cambridge University Press..
https://doi.org/10.1017/S0022215123001974

Perić A, Gaćeša D, Vezmar-Kovačević S, Perić AV, Vojvodić D, Georgiou S, Protopapadakis E, Alevizopoulos K. The effect of nasal douching by hypertonic 2.3% sea water with algae extracts on the concentration of epidermal growth factor, transforming growth factor-α and interleukin-8 in nasal secretions of patients with nasal polyposis following endoscopic surgical treatment. in Journal of Laryngology and Otology. 2023;.
doi:10.1017/S0022215123001974 .

Perić, Aleksandar, Gaćeša, Dejan, Vezmar-Kovačević, Sandra, Perić, Aneta V., Vojvodić, Danilo, Georgiou, Stella, Protopapadakis, Evdokia, Alevizopoulos, Konstantinos, "The effect of nasal douching by hypertonic 2.3% sea water with algae extracts on the concentration of epidermal growth factor, transforming growth factor-α and interleukin-8 in nasal secretions of patients with nasal polyposis following endoscopic surgical treatment" in Journal of Laryngology and Otology (2023),
https://doi.org/10.1017/S0022215123001974 . .

TY  - JOUR
AU  - Jovanović, Marija
AU  - Kovačević, Milena
AU  - Catić-Đorđević, Aleksandra
AU  - Ćulafić, Milica
AU  - Stefanović, Nikola
AU  - Mitić, Branka
AU  - Vučićević, Katarina
AU  - Vezmar-Kovačević, Sandra
AU  - Veličković-Radovanović, Radmila
AU  - Miljković, Branislava
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4921
AB  - The study aimed to estimate and compare the prevalence and type of potentially inappropriate medications (PIMs) and potential prescribing omissions (PPOs) between the STOPP/START original (v1) and updated version (v2) among older patients in various settings, as well as associated factors. The study included 440 patients attending a community pharmacy, 200 outpatients and 140 nursing home users. An increase in the prevalence of STOPP v2 (57.9%) compared to v1 (56.2%) was not statistically significant in the total sample and within each setting (p>0.05). A decrease in the prevalence of START v1 (55.8%) to v2 (41.2%) was statistically significant (p<0.001) in the total sample and within each setting (p<0.05). Drug indication (32.9%) and fall-risk medications (32.2%) were most commonly identified for STOPP v2, while cardiovascular system criteria (30.5%) were the most frequently detected for START v2. The number of medications was the strongest predictor for both STOPP v1 and v2, with odds ratio values of 1.35 and 1.34, respectively. Patients’ characteristics associated with the occurrence of STOPP and START criteria were identified. According to both STOPP/START versions, the results indicate a substantial rate of potentially inappropriate prescribing among elderly patients. The prevalence of PIMs was slightly higher with the updated version, while the prevalence of PPOs was significantly lower.
T2  - Brazilian Journal of Pharmaceutical Sciences
T1  - Potentially inappropriate prescribing among older patients and associated factors: comparison of two versions of STOPP/START criteria
VL  - 59
DO  - 10.1590/s2175-97902023e22549
ER  - 

@article{
author = "Jovanović, Marija and Kovačević, Milena and Catić-Đorđević, Aleksandra and Ćulafić, Milica and Stefanović, Nikola and Mitić, Branka and Vučićević, Katarina and Vezmar-Kovačević, Sandra and Veličković-Radovanović, Radmila and Miljković, Branislava",
year = "2023",
abstract = "The study aimed to estimate and compare the prevalence and type of potentially inappropriate medications (PIMs) and potential prescribing omissions (PPOs) between the STOPP/START original (v1) and updated version (v2) among older patients in various settings, as well as associated factors. The study included 440 patients attending a community pharmacy, 200 outpatients and 140 nursing home users. An increase in the prevalence of STOPP v2 (57.9%) compared to v1 (56.2%) was not statistically significant in the total sample and within each setting (p>0.05). A decrease in the prevalence of START v1 (55.8%) to v2 (41.2%) was statistically significant (p<0.001) in the total sample and within each setting (p<0.05). Drug indication (32.9%) and fall-risk medications (32.2%) were most commonly identified for STOPP v2, while cardiovascular system criteria (30.5%) were the most frequently detected for START v2. The number of medications was the strongest predictor for both STOPP v1 and v2, with odds ratio values of 1.35 and 1.34, respectively. Patients’ characteristics associated with the occurrence of STOPP and START criteria were identified. According to both STOPP/START versions, the results indicate a substantial rate of potentially inappropriate prescribing among elderly patients. The prevalence of PIMs was slightly higher with the updated version, while the prevalence of PPOs was significantly lower.",
journal = "Brazilian Journal of Pharmaceutical Sciences",
title = "Potentially inappropriate prescribing among older patients and associated factors: comparison of two versions of STOPP/START criteria",
volume = "59",
doi = "10.1590/s2175-97902023e22549"
}

Jovanović, M., Kovačević, M., Catić-Đorđević, A., Ćulafić, M., Stefanović, N., Mitić, B., Vučićević, K., Vezmar-Kovačević, S., Veličković-Radovanović, R.,& Miljković, B.. (2023). Potentially inappropriate prescribing among older patients and associated factors: comparison of two versions of STOPP/START criteria. in Brazilian Journal of Pharmaceutical Sciences, 59.
https://doi.org/10.1590/s2175-97902023e22549

Jovanović M, Kovačević M, Catić-Đorđević A, Ćulafić M, Stefanović N, Mitić B, Vučićević K, Vezmar-Kovačević S, Veličković-Radovanović R, Miljković B. Potentially inappropriate prescribing among older patients and associated factors: comparison of two versions of STOPP/START criteria. in Brazilian Journal of Pharmaceutical Sciences. 2023;59.
doi:10.1590/s2175-97902023e22549 .

Jovanović, Marija, Kovačević, Milena, Catić-Đorđević, Aleksandra, Ćulafić, Milica, Stefanović, Nikola, Mitić, Branka, Vučićević, Katarina, Vezmar-Kovačević, Sandra, Veličković-Radovanović, Radmila, Miljković, Branislava, "Potentially inappropriate prescribing among older patients and associated factors: comparison of two versions of STOPP/START criteria" in Brazilian Journal of Pharmaceutical Sciences, 59 (2023),
https://doi.org/10.1590/s2175-97902023e22549 . .

TY  - JOUR
AU  - Jovanović, Marija
AU  - Kovačević, Milena
AU  - Vezmar-Kovačević, Sandra
AU  - Palibrk, Ivan
AU  - Bjelanović, Jasna
AU  - Miljković, Branislava
AU  - Vučićević, Katarina
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4378
AB  - Background: The study aimed to estimate lidocaine (LID)
pharmacokinetic parameter values in patients with
impaired liver function, level of correlation between the
pharmacokinetic parameters and Child-Pugh class and
change in pharmacokinetic parameters after liver tumor
resection compared to the preoperative value.
Methods: Patients with impaired liver function were subject
to the LID test 1 day prior to, 3 and 7 days after the inter-
vention. LID was administered in single i.v. dose of 1 mg/kg.
Blood samples were collected at 15, 30 and 90 minutes
after drug administration. Non-compartmental analysis was
applied for calculating the pharmacokinetic parameters.
Results: The study included 17 patients with the diagnosis of
cirrhosis and 41 patients with liver tumor. In both groups of
patients, the values of the coefficients of correlation show
the best correlation between clearance (CL) and Child-Pugh
score (-0.693, p<0.005) over other pharmacokinetic
parameters. The results indicate worsening hepatic function
on 3rd day after operation in comparison to the values of
LID CL prior to operation (mean LID CL for patients with
Child-Pugh class A are 25.91 L/h, 41.59 L/h, respectively;
while for B class are 16.89 L/h, 22.65 L/h, respectively). On
day 7th, the values of LID CL (mean value for patients with
Child-Pugh class A and B are 40.98 L/h and 21.46 L/h,
respectively) are increased in comparison to 3rd day after.
Conclusions: LID pharmacokinetic parameters consequent-
ly changed according to the severity of liver impairment,
assessed by Child-Pugh score. Values of LID CL and vol-
ume of distribution (Vd) coupled with standard biochemical
parameters may be used for preoperative assessment of
liver function and monitoring of its postoperative recovery.
AB  - Uvod: Cilj studije bila je procena vrednosti farmako-
kinetičkih parametara lidokaina (LID) kod pacijenata sa
oštećenom funkcijom jetre, stepena korelacije izme|u
farmakokinetičkih parametara i Child-Pugh klase i promene farmakokinetičkih parametara posle resekcije tumora
jetre u odnosu na preoperativnu vrednost.
Metode: Pacijenti sa o{te}enom funkcijom jetre bili su
podvrgnuti LID testu 1 dan pre, 3. i 7. dana nakon
intervencije. LID je primenjen u pojedinačnoj i.v. dozi od 1
mg/kg. Uzorci krvi su sakupljeni 15, 30 i 90 minuta nakon
primene leka. Za izračunavanje farmakokinetičkih
parametara primenjena je neprostorna analiza.
Rezultati: Studijom je obuhvaćeno 17 pacijenata sa
dijagnozom ciroze i 41 pacijent sa tumorom jetre. Kod obe
grupe pacijenata, vrednosti koeficijenata korelacije
pokazuju najbolju korelaciju izme|u klirensa LID (CL) i
Child-Pugh skora (-0,693, p<0,005) u odnosu na ostale
farmakokinetičke parametre. Rezultati ukazuju na pogoršanje funkcije jetre 3. dana nakon operacije u pore|enju sa
vrednostima LID CL pre operacije (srednje vrednosti LID CL
kod pacijenata Child-Pugh grupe A iznosile su 25,91 L/h,
41,59 L/h, respektivno; dok su kod pacijenata u klasi B
iznosile 16,89 L/h, 22,65 L/h, respektivno). Sedmog dana
vrednosti LID CL (srednja vrednost u Child-Pugh grupi A i B
iznosile su 40,98 L/h i 21,46 L/h, respektivno) bile su veće
u odnosu na 3. dan posle hirur{ke intervencije.
Zaključak: Farmakokinetički parametri LID se razlikuju u
zavisnosti od težine oštećenja jetre, procenjenih Child-Pugh
skorom. Vrednosti farmakokinetičkih parametara LID u
kombinaciji sa standardnim biohemijskim parametrima
mogu se koristiti za preoperativnu procenu funkcije jetre i
praćenje njenog postoperativnog oporavka
PB  - Beograd : Društvo medicinskih biohemičara Srbije
T2  - Journal of Medical Biochemistry
T1  - Lidocaine Clearance as Pharmacokinetic Parameter of Metabolic Hepatic Activity in Patients with Impaired Liver
T1  - Klirens lidokaina kao farmakokinetički parametar metaboličke aktivnosti kod pacijenata sa oštećenjem jetre
VL  - 42
SP  - 1
EP  - 7
DO  - 10.5937/jomb0-38952
ER  - 

@article{
author = "Jovanović, Marija and Kovačević, Milena and Vezmar-Kovačević, Sandra and Palibrk, Ivan and Bjelanović, Jasna and Miljković, Branislava and Vučićević, Katarina",
year = "2023",
abstract = "Background: The study aimed to estimate lidocaine (LID)
pharmacokinetic parameter values in patients with
impaired liver function, level of correlation between the
pharmacokinetic parameters and Child-Pugh class and
change in pharmacokinetic parameters after liver tumor
resection compared to the preoperative value.
Methods: Patients with impaired liver function were subject
to the LID test 1 day prior to, 3 and 7 days after the inter-
vention. LID was administered in single i.v. dose of 1 mg/kg.
Blood samples were collected at 15, 30 and 90 minutes
after drug administration. Non-compartmental analysis was
applied for calculating the pharmacokinetic parameters.
Results: The study included 17 patients with the diagnosis of
cirrhosis and 41 patients with liver tumor. In both groups of
patients, the values of the coefficients of correlation show
the best correlation between clearance (CL) and Child-Pugh
score (-0.693, p<0.005) over other pharmacokinetic
parameters. The results indicate worsening hepatic function
on 3rd day after operation in comparison to the values of
LID CL prior to operation (mean LID CL for patients with
Child-Pugh class A are 25.91 L/h, 41.59 L/h, respectively;
while for B class are 16.89 L/h, 22.65 L/h, respectively). On
day 7th, the values of LID CL (mean value for patients with
Child-Pugh class A and B are 40.98 L/h and 21.46 L/h,
respectively) are increased in comparison to 3rd day after.
Conclusions: LID pharmacokinetic parameters consequent-
ly changed according to the severity of liver impairment,
assessed by Child-Pugh score. Values of LID CL and vol-
ume of distribution (Vd) coupled with standard biochemical
parameters may be used for preoperative assessment of
liver function and monitoring of its postoperative recovery., Uvod: Cilj studije bila je procena vrednosti farmako-
kinetičkih parametara lidokaina (LID) kod pacijenata sa
oštećenom funkcijom jetre, stepena korelacije izme|u
farmakokinetičkih parametara i Child-Pugh klase i promene farmakokinetičkih parametara posle resekcije tumora
jetre u odnosu na preoperativnu vrednost.
Metode: Pacijenti sa o{te}enom funkcijom jetre bili su
podvrgnuti LID testu 1 dan pre, 3. i 7. dana nakon
intervencije. LID je primenjen u pojedinačnoj i.v. dozi od 1
mg/kg. Uzorci krvi su sakupljeni 15, 30 i 90 minuta nakon
primene leka. Za izračunavanje farmakokinetičkih
parametara primenjena je neprostorna analiza.
Rezultati: Studijom je obuhvaćeno 17 pacijenata sa
dijagnozom ciroze i 41 pacijent sa tumorom jetre. Kod obe
grupe pacijenata, vrednosti koeficijenata korelacije
pokazuju najbolju korelaciju izme|u klirensa LID (CL) i
Child-Pugh skora (-0,693, p<0,005) u odnosu na ostale
farmakokinetičke parametre. Rezultati ukazuju na pogoršanje funkcije jetre 3. dana nakon operacije u pore|enju sa
vrednostima LID CL pre operacije (srednje vrednosti LID CL
kod pacijenata Child-Pugh grupe A iznosile su 25,91 L/h,
41,59 L/h, respektivno; dok su kod pacijenata u klasi B
iznosile 16,89 L/h, 22,65 L/h, respektivno). Sedmog dana
vrednosti LID CL (srednja vrednost u Child-Pugh grupi A i B
iznosile su 40,98 L/h i 21,46 L/h, respektivno) bile su veće
u odnosu na 3. dan posle hirur{ke intervencije.
Zaključak: Farmakokinetički parametri LID se razlikuju u
zavisnosti od težine oštećenja jetre, procenjenih Child-Pugh
skorom. Vrednosti farmakokinetičkih parametara LID u
kombinaciji sa standardnim biohemijskim parametrima
mogu se koristiti za preoperativnu procenu funkcije jetre i
praćenje njenog postoperativnog oporavka",
publisher = "Beograd : Društvo medicinskih biohemičara Srbije",
journal = "Journal of Medical Biochemistry",
title = "Lidocaine Clearance as Pharmacokinetic Parameter of Metabolic Hepatic Activity in Patients with Impaired Liver, Klirens lidokaina kao farmakokinetički parametar metaboličke aktivnosti kod pacijenata sa oštećenjem jetre",
volume = "42",
pages = "1-7",
doi = "10.5937/jomb0-38952"
}

Jovanović, M., Kovačević, M., Vezmar-Kovačević, S., Palibrk, I., Bjelanović, J., Miljković, B.,& Vučićević, K.. (2023). Lidocaine Clearance as Pharmacokinetic Parameter of Metabolic Hepatic Activity in Patients with Impaired Liver. in Journal of Medical Biochemistry
Beograd : Društvo medicinskih biohemičara Srbije., 42, 1-7.
https://doi.org/10.5937/jomb0-38952

Jovanović M, Kovačević M, Vezmar-Kovačević S, Palibrk I, Bjelanović J, Miljković B, Vučićević K. Lidocaine Clearance as Pharmacokinetic Parameter of Metabolic Hepatic Activity in Patients with Impaired Liver. in Journal of Medical Biochemistry. 2023;42:1-7.
doi:10.5937/jomb0-38952 .

Jovanović, Marija, Kovačević, Milena, Vezmar-Kovačević, Sandra, Palibrk, Ivan, Bjelanović, Jasna, Miljković, Branislava, Vučićević, Katarina, "Lidocaine Clearance as Pharmacokinetic Parameter of Metabolic Hepatic Activity in Patients with Impaired Liver" in Journal of Medical Biochemistry, 42 (2023):1-7,
https://doi.org/10.5937/jomb0-38952 . .

TY  - CONF
AU  - Vezmar-Kovačević, Sandra
AU  - Odalović, Marina
AU  - Tadić, Ivana
AU  - Vučićević, Katarina
AU  - Malenović, Anđelija
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4822
AB  - Introduction: At the Faculty of Pharmacy University of Belgrade, the Objective Structured Clinical Examination (0SCE) was introduced to assess clinical competences and communication skills of pharmacy students following their 6-weeks practice in public pharmacies during the 10th semester. Methods: The OSCE consisted of one patient case that was presented to the student firstly in a short written form. The patient case had at least one drug-related problem that the student was expected to identify and solve. A teaching assistant played the role of the patient and a teacher assessed the communication skills and clinical competences during the student's interview with the „patient" using a structured form (checklist). The student had limited time (7 minutes) to identify and solve the drug-related problem(s) and to councel the patient. The use of a Drug register and Pharmacotherapy guide were allowed. Results: One hundred fifty students completed the OSCE so far. The students could achieve O-40 points during the exam, according to their performance. The maximal point score was achieved if the student obtained all relevant information from the patient”, identified and solved the drug-related problem(s) and offered appropriate information. The minimal point score (0) was assigned if the student made an error which could harm the patient. The median result of the OSCE was 28 points (interquatile range 10), while 7 students (4.7%) scored 0-9 points, 12 (8.0%) scored 10-19 points, 68 (45.3%) scored 20-29 points, 58 (38.79%) scored 30-39 points and 5 students (3.3%) scored 40 points. Conclusions: The introduction of the OSCE was successful and enabled the teaching staff to obtain a more accurate knowledge of the students’ clinical competences and communication skills as well as to identify gaps in the competences in skills which need to be improved.
PB  - European Association of Faculties of Pharmacy
C3  - EAFP Conference 2022, Towards Pharmacy 5.0 Education - Abstract Book
T1  - Introduction of an Objective Structured Clinical Examination for Pharmacy Students in Serbia
SP  - 47
EP  - 47
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4822
ER  - 

@conference{
author = "Vezmar-Kovačević, Sandra and Odalović, Marina and Tadić, Ivana and Vučićević, Katarina and Malenović, Anđelija",
year = "2022",
abstract = "Introduction: At the Faculty of Pharmacy University of Belgrade, the Objective Structured Clinical Examination (0SCE) was introduced to assess clinical competences and communication skills of pharmacy students following their 6-weeks practice in public pharmacies during the 10th semester. Methods: The OSCE consisted of one patient case that was presented to the student firstly in a short written form. The patient case had at least one drug-related problem that the student was expected to identify and solve. A teaching assistant played the role of the patient and a teacher assessed the communication skills and clinical competences during the student's interview with the „patient" using a structured form (checklist). The student had limited time (7 minutes) to identify and solve the drug-related problem(s) and to councel the patient. The use of a Drug register and Pharmacotherapy guide were allowed. Results: One hundred fifty students completed the OSCE so far. The students could achieve O-40 points during the exam, according to their performance. The maximal point score was achieved if the student obtained all relevant information from the patient”, identified and solved the drug-related problem(s) and offered appropriate information. The minimal point score (0) was assigned if the student made an error which could harm the patient. The median result of the OSCE was 28 points (interquatile range 10), while 7 students (4.7%) scored 0-9 points, 12 (8.0%) scored 10-19 points, 68 (45.3%) scored 20-29 points, 58 (38.79%) scored 30-39 points and 5 students (3.3%) scored 40 points. Conclusions: The introduction of the OSCE was successful and enabled the teaching staff to obtain a more accurate knowledge of the students’ clinical competences and communication skills as well as to identify gaps in the competences in skills which need to be improved.",
publisher = "European Association of Faculties of Pharmacy",
journal = "EAFP Conference 2022, Towards Pharmacy 5.0 Education - Abstract Book",
title = "Introduction of an Objective Structured Clinical Examination for Pharmacy Students in Serbia",
pages = "47-47",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4822"
}

Vezmar-Kovačević, S., Odalović, M., Tadić, I., Vučićević, K.,& Malenović, A.. (2022). Introduction of an Objective Structured Clinical Examination for Pharmacy Students in Serbia. in EAFP Conference 2022, Towards Pharmacy 5.0 Education - Abstract Book
European Association of Faculties of Pharmacy., 47-47.
https://hdl.handle.net/21.15107/rcub_farfar_4822

Vezmar-Kovačević S, Odalović M, Tadić I, Vučićević K, Malenović A. Introduction of an Objective Structured Clinical Examination for Pharmacy Students in Serbia. in EAFP Conference 2022, Towards Pharmacy 5.0 Education - Abstract Book. 2022;:47-47.
https://hdl.handle.net/21.15107/rcub_farfar_4822 .

Vezmar-Kovačević, Sandra, Odalović, Marina, Tadić, Ivana, Vučićević, Katarina, Malenović, Anđelija, "Introduction of an Objective Structured Clinical Examination for Pharmacy Students in Serbia" in EAFP Conference 2022, Towards Pharmacy 5.0 Education - Abstract Book (2022):47-47,
https://hdl.handle.net/21.15107/rcub_farfar_4822 .

TY  - JOUR
AU  - Kovačević, Milena
AU  - Ćulafić, Milica
AU  - Vezmar-Kovačević, Sandra
AU  - Borjanić, Slavenka
AU  - Keleč, Branka
AU  - Miljković, Branislava
AU  - Amidžić, Rada
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3973
AB  - The COVID-19 pandemic exerted a profound impact on health systems worldwide. Moreover, significant concerns were raised in terms of middle- and long-term consequences of postponing care in non-COVID patients. The primary aim of the study was to describe the remote pharmaceutical care service (telepharmacy) during the COVID-19 pandemic in the Republic of Srpska (RS), Bosnia and Herzegovina. The secondary aim was to identify service users’ needs and concerns and to describe community pharmacists’ interventions. Ten community pharmacists were appointed by the Pharmaceutical Society of the RS to deliver telepharmacy services. After obtaining users’ verbal permission, pharmacists documented issues discussed with them. The prospective data collection included the period from April 13 to May 21, 2020. Descriptive and statistical analysis was performed using IBM SPSS Statistics software (ver. 22). A total of 71 service users’ charts were analyzed. Telepharmacy users were on average 61.31 ± 13.27 years of age, with almost equal gender distribution. Patients with chronic or acute/subacute conditions were predominant with a share of 84.5%. Chronic diseases were the main reason for searching pharmacists’ consultation (74.6%), 7% had a complaint about worsening of a chronic condition, 9.9% reported only acute/subacute conditions as ambulatory conditions, whereas 15.5% asked information about coronavirus or COVID-19. The vast majority of patients’ and users’ needs were addressed by a pharmacist during counseling and only 15.5% of the patients required immediate referral to a doctor for refill/prescribing purposes. Remote pharmaceutical care service (telepharmacy) is deemed a convenient model in the RS during the COVID-19 pandemic. Patients and users presented with explicit and specific needs and concerns, both COVID- and non-COVID-related, which should not be neglected. Community pharmacists showed a high level of resilience and ability in addressing patients' needs.
PB  - John Wiley and Sons Inc
T2  - Health and Social Care in the Community
T1  - Telepharmacy service experience during the COVID-19 pandemic in the Republic of Srpska, Bosnia and Herzegovina
VL  - 30
IS  - 5
SP  - e1639
EP  - e1650
DO  - 10.1111/hsc.13590
ER  - 

@article{
author = "Kovačević, Milena and Ćulafić, Milica and Vezmar-Kovačević, Sandra and Borjanić, Slavenka and Keleč, Branka and Miljković, Branislava and Amidžić, Rada",
year = "2022",
abstract = "The COVID-19 pandemic exerted a profound impact on health systems worldwide. Moreover, significant concerns were raised in terms of middle- and long-term consequences of postponing care in non-COVID patients. The primary aim of the study was to describe the remote pharmaceutical care service (telepharmacy) during the COVID-19 pandemic in the Republic of Srpska (RS), Bosnia and Herzegovina. The secondary aim was to identify service users’ needs and concerns and to describe community pharmacists’ interventions. Ten community pharmacists were appointed by the Pharmaceutical Society of the RS to deliver telepharmacy services. After obtaining users’ verbal permission, pharmacists documented issues discussed with them. The prospective data collection included the period from April 13 to May 21, 2020. Descriptive and statistical analysis was performed using IBM SPSS Statistics software (ver. 22). A total of 71 service users’ charts were analyzed. Telepharmacy users were on average 61.31 ± 13.27 years of age, with almost equal gender distribution. Patients with chronic or acute/subacute conditions were predominant with a share of 84.5%. Chronic diseases were the main reason for searching pharmacists’ consultation (74.6%), 7% had a complaint about worsening of a chronic condition, 9.9% reported only acute/subacute conditions as ambulatory conditions, whereas 15.5% asked information about coronavirus or COVID-19. The vast majority of patients’ and users’ needs were addressed by a pharmacist during counseling and only 15.5% of the patients required immediate referral to a doctor for refill/prescribing purposes. Remote pharmaceutical care service (telepharmacy) is deemed a convenient model in the RS during the COVID-19 pandemic. Patients and users presented with explicit and specific needs and concerns, both COVID- and non-COVID-related, which should not be neglected. Community pharmacists showed a high level of resilience and ability in addressing patients' needs.",
publisher = "John Wiley and Sons Inc",
journal = "Health and Social Care in the Community",
title = "Telepharmacy service experience during the COVID-19 pandemic in the Republic of Srpska, Bosnia and Herzegovina",
volume = "30",
number = "5",
pages = "e1639-e1650",
doi = "10.1111/hsc.13590"
}

Kovačević, M., Ćulafić, M., Vezmar-Kovačević, S., Borjanić, S., Keleč, B., Miljković, B.,& Amidžić, R.. (2022). Telepharmacy service experience during the COVID-19 pandemic in the Republic of Srpska, Bosnia and Herzegovina. in Health and Social Care in the Community
John Wiley and Sons Inc., 30(5), e1639-e1650.
https://doi.org/10.1111/hsc.13590

Kovačević M, Ćulafić M, Vezmar-Kovačević S, Borjanić S, Keleč B, Miljković B, Amidžić R. Telepharmacy service experience during the COVID-19 pandemic in the Republic of Srpska, Bosnia and Herzegovina. in Health and Social Care in the Community. 2022;30(5):e1639-e1650.
doi:10.1111/hsc.13590 .

Kovačević, Milena, Ćulafić, Milica, Vezmar-Kovačević, Sandra, Borjanić, Slavenka, Keleč, Branka, Miljković, Branislava, Amidžić, Rada, "Telepharmacy service experience during the COVID-19 pandemic in the Republic of Srpska, Bosnia and Herzegovina" in Health and Social Care in the Community, 30, no. 5 (2022):e1639-e1650,
https://doi.org/10.1111/hsc.13590 . .

TY  - JOUR
AU  - Milenković, Bojana
AU  - Šuljagić, Vesna
AU  - Perić, Aneta
AU  - Dragojević-Simić, Viktorija
AU  - Tarabar, Olivera
AU  - Milanović, Milomir
AU  - Putić, Vesna
AU  - Tomić, Diana
AU  - Miljković, Branislava
AU  - Vezmar-Kovačević, Sandra
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4829
AB  - Background Clostridioides difficile infection (CDI) is one of the most common healthcare-associated (HA) infections. Cancer patients, particularly haemato-oncological patients, have an increased risk for CDI due to more risk factors compared with non-cancer patients. The aim of this study was to investigate differences in outcomes associated with HA CDI in patients with solid and haematological malignancies compared with patients with no underlying malignant disease in a tertiary healthcare centre in Serbia.

Methods A prospective cohort study was conducted including adult patients diagnosed with an initial episode of HA CDI. Their demographic and clinical characteristics associated with risk factors for CDI were documented. Outcomes such as all-cause 30-day mortality, cure of infection, diarrhoea relaps and recurrence of disease were followed. Patients were assigned to cancer and non-cancer groups. Within the cancer group, patients were divided into the solid tumour subgroup and haematological malignancy subgroup.

Results During a 7-year period, HA CDI was observed in 28 (5.1%) patients with haematological malignancy, 101 (18.3%) patients with solid tumours and 424 (76.7%) non-cancer patients. Older age (OR 1.04, 95% CI 1.02 to 1.07, p<0.001), admission to the intensive care unit (ICU) (OR 2.61, 95% CI 1.37 to 4.95, p=0.003), mechanical ventilation (OR 5.19, 95% CI 2.78 to 9.71, p<0.001) and use of antibiotics prior to CDI (OR 1.04, 95% CI 1.02 to 1.06, p=0.02) were associated with increased mortality. Compared with patients with solid tumours, patients with haematological malignancy were younger (65 vs 57 years, p=0.015), did not require ICU admission (25.0% vs 0%) or mechanical ventilation (8.9% vs 0%) and were treated longer with antibiotics prior to CDI (14 vs 24 days, p=0.002).

Conclusions Patients with haematological malignancy were exposed to different risk factors for CDI associated with mortality compared with patients with solid tumours and non-cancer patients. Older age, ICU stay and mechanical ventilation, but not presence or type of cancer, predicted the all-cause 30-day mortality.
PB  - British Medical Journal
T2  - European Journal of Hospital Pharmacy
T1  - Outcomes of Clostridioides difficile infection in adult cancer and non-cancer patients hospitalised in a tertiary hospital: a prospective cohort study
VL  - 29
IS  - e1
SP  - e15
EP  - e22
DO  - 10.1136/ejhpharm-2020-002574
ER  - 

@article{
author = "Milenković, Bojana and Šuljagić, Vesna and Perić, Aneta and Dragojević-Simić, Viktorija and Tarabar, Olivera and Milanović, Milomir and Putić, Vesna and Tomić, Diana and Miljković, Branislava and Vezmar-Kovačević, Sandra",
year = "2022",
abstract = "Background Clostridioides difficile infection (CDI) is one of the most common healthcare-associated (HA) infections. Cancer patients, particularly haemato-oncological patients, have an increased risk for CDI due to more risk factors compared with non-cancer patients. The aim of this study was to investigate differences in outcomes associated with HA CDI in patients with solid and haematological malignancies compared with patients with no underlying malignant disease in a tertiary healthcare centre in Serbia.

Methods A prospective cohort study was conducted including adult patients diagnosed with an initial episode of HA CDI. Their demographic and clinical characteristics associated with risk factors for CDI were documented. Outcomes such as all-cause 30-day mortality, cure of infection, diarrhoea relaps and recurrence of disease were followed. Patients were assigned to cancer and non-cancer groups. Within the cancer group, patients were divided into the solid tumour subgroup and haematological malignancy subgroup.

Results During a 7-year period, HA CDI was observed in 28 (5.1%) patients with haematological malignancy, 101 (18.3%) patients with solid tumours and 424 (76.7%) non-cancer patients. Older age (OR 1.04, 95% CI 1.02 to 1.07, p<0.001), admission to the intensive care unit (ICU) (OR 2.61, 95% CI 1.37 to 4.95, p=0.003), mechanical ventilation (OR 5.19, 95% CI 2.78 to 9.71, p<0.001) and use of antibiotics prior to CDI (OR 1.04, 95% CI 1.02 to 1.06, p=0.02) were associated with increased mortality. Compared with patients with solid tumours, patients with haematological malignancy were younger (65 vs 57 years, p=0.015), did not require ICU admission (25.0% vs 0%) or mechanical ventilation (8.9% vs 0%) and were treated longer with antibiotics prior to CDI (14 vs 24 days, p=0.002).

Conclusions Patients with haematological malignancy were exposed to different risk factors for CDI associated with mortality compared with patients with solid tumours and non-cancer patients. Older age, ICU stay and mechanical ventilation, but not presence or type of cancer, predicted the all-cause 30-day mortality.",
publisher = "British Medical Journal",
journal = "European Journal of Hospital Pharmacy",
title = "Outcomes of Clostridioides difficile infection in adult cancer and non-cancer patients hospitalised in a tertiary hospital: a prospective cohort study",
volume = "29",
number = "e1",
pages = "e15-e22",
doi = "10.1136/ejhpharm-2020-002574"
}

Milenković, B., Šuljagić, V., Perić, A., Dragojević-Simić, V., Tarabar, O., Milanović, M., Putić, V., Tomić, D., Miljković, B.,& Vezmar-Kovačević, S.. (2022). Outcomes of Clostridioides difficile infection in adult cancer and non-cancer patients hospitalised in a tertiary hospital: a prospective cohort study. in European Journal of Hospital Pharmacy
British Medical Journal., 29(e1), e15-e22.
https://doi.org/10.1136/ejhpharm-2020-002574

Milenković B, Šuljagić V, Perić A, Dragojević-Simić V, Tarabar O, Milanović M, Putić V, Tomić D, Miljković B, Vezmar-Kovačević S. Outcomes of Clostridioides difficile infection in adult cancer and non-cancer patients hospitalised in a tertiary hospital: a prospective cohort study. in European Journal of Hospital Pharmacy. 2022;29(e1):e15-e22.
doi:10.1136/ejhpharm-2020-002574 .

Milenković, Bojana, Šuljagić, Vesna, Perić, Aneta, Dragojević-Simić, Viktorija, Tarabar, Olivera, Milanović, Milomir, Putić, Vesna, Tomić, Diana, Miljković, Branislava, Vezmar-Kovačević, Sandra, "Outcomes of Clostridioides difficile infection in adult cancer and non-cancer patients hospitalised in a tertiary hospital: a prospective cohort study" in European Journal of Hospital Pharmacy, 29, no. e1 (2022):e15-e22,
https://doi.org/10.1136/ejhpharm-2020-002574 . .

TY  - CONF
AU  - Jovanović, Marija
AU  - Ćulafić, Milica
AU  - Pejić, Nina
AU  - Štulić, Miloš
AU  - Kovačević, Milena
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
AU  - Ćulafić, Đorđe
AU  - Vučićević, Katarina
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4531
AB  - Tacrolimus is an immunosuppressant used to prevent graft rejection after liver
transplantation. The narrow therapeutic range and great variability in pharmacokinetics
indicate the need for therapy individualization. The aim of the study was to develop and
validate the base pharmacokinetic model of tacrolimus using data collected during
therapeutic drug monitoring. The study included 29 liver transplant recipients followed up
at Clinic for Gastroenterology and Hepatology, Clinical Center of Serbia. Using the
NONMEM® program, we analyzed tacrolimus concentrations (Ctrough) measured in whole
blood (260). Pharmacokinetics have been described as one-compartment model with first-
order absorption and elimination. Internal validation was performed using graphical
assessment, bootstrap method and visual predictive check (VPC). Typical value of oral
clearance (CL/F) was 30.4 L/h, while value of oral volume of distribution was 5770 L. The
value of the absorption rate constant was fixed at 4.48 h-1 . Interindividual variability was
best described by the exponential model, and residual by the additive model. Interindividual
variability for CL/F was 38.2%. Individual predicted concentrations (IPRED) showed better
agreement with the measured values than population predicted values (PRED). Conditional
weighted residuals (CWRES vs PRED, CWRES vs TIME) were mostly between -2 and +2
standard deviations. The parameters obtained by bootstrap analysis do not deviate
significantly from the model. Median, 5th and 95th percentiles in the VPC method mostly
were within the simulated 95% confidence interval. The obtained population
pharmacokinetic model, after additional optimization, can be used for individualization of
the tacrolimus dosing regimen in the population of liver transplant recipients.
AB  - Takrolimus je imunosupresiv koji se primenjuje za prevenciju odbacivanja grafta
nakon transplantacije jetre. Uzak terapijski opseg i velika varijabilnost u farmakokinetici
ukazuju na neophodnost individualizacije terapije. Cilj istraživanja bio je razvoj i validacija
osnovnog farmakokinetičkog modela takrolimusa baziranog na podacima prikupljenim
tokom terapijskog praćenja leka. Studija je uključila 29 pacijenata sa transplantiranom
jetrom, praćenih na Klinici za gastroenterologiju i hepatologiju, Kliničkog centra Srbije.
Primenom NONMEM® programa analizirane su koncentracije takrolimusa izmerene u punoj
krvi (260), neposredno pre primene jutarnje doze (Ctrough). Farmakokinetika je opisana
jednoprostornim modelom sa resorpcijom i eliminacijom prvog reda. Interna validacija je
vršena primenom grafičke metode procene, metode umnožavanja podataka (bootstrap) i
vizuelne prediktivne provere (VPC). Procenjena tipična vrednost oralnog klirensa (CL/F)
iznosila je 30,4 L/h, dok je vrednost oralnog volumena distribucije bila 5770 L. Vrednost
konstante brzine resorpcije je fiksirana na 4,48 h-1 . Interindividualna varijabilnost je najbolje
opisana eksponencijalnim modelom, a rezidualna aditivnim modelom. Zabeležena je
interindividualna varijabilnost za CL/F od 38,2%. Predviđene individualne koncentracije
(IPRED) pokazuju bolje slaganje sa izmerenim vrednostima, nego populacione predviđene
vrednosti (PRED). Uslovni težinski reziduali (CWRES vs PRED, CWRES vs TIME) su većinom
raspoređeni između -2 i +2 standardne devijacije. Parametri dobijeni bootstrap analizom ne
odstupaju značajno od modela, dok su vrednosti medijane, 5. i 95. percentila u VPC metodi
uglavnom bile u okviru simuliranih 95% intervala pouzdanosti. Dobijeni populacioni
farmakokinetički model, može se nakon dodatne optimizacije, primeniti u svrhu
individualizacije režima doziranja takrolimusa u populaciji pacijenata sa transplantiranom
jetrom.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - A population pharmacokinetic model of tacrolimus in adult liver transplant recipients
T1  - Populacioni farmakokinetički model takrolimusa kod pacijenata sa transplantiranom jetrom
VL  - 72
IS  - 4 suplement
SP  - S298
EP  - S299
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4531
ER  - 

@conference{
author = "Jovanović, Marija and Ćulafić, Milica and Pejić, Nina and Štulić, Miloš and Kovačević, Milena and Vezmar-Kovačević, Sandra and Miljković, Branislava and Ćulafić, Đorđe and Vučićević, Katarina",
year = "2022",
abstract = "Tacrolimus is an immunosuppressant used to prevent graft rejection after liver
transplantation. The narrow therapeutic range and great variability in pharmacokinetics
indicate the need for therapy individualization. The aim of the study was to develop and
validate the base pharmacokinetic model of tacrolimus using data collected during
therapeutic drug monitoring. The study included 29 liver transplant recipients followed up
at Clinic for Gastroenterology and Hepatology, Clinical Center of Serbia. Using the
NONMEM® program, we analyzed tacrolimus concentrations (Ctrough) measured in whole
blood (260). Pharmacokinetics have been described as one-compartment model with first-
order absorption and elimination. Internal validation was performed using graphical
assessment, bootstrap method and visual predictive check (VPC). Typical value of oral
clearance (CL/F) was 30.4 L/h, while value of oral volume of distribution was 5770 L. The
value of the absorption rate constant was fixed at 4.48 h-1 . Interindividual variability was
best described by the exponential model, and residual by the additive model. Interindividual
variability for CL/F was 38.2%. Individual predicted concentrations (IPRED) showed better
agreement with the measured values than population predicted values (PRED). Conditional
weighted residuals (CWRES vs PRED, CWRES vs TIME) were mostly between -2 and +2
standard deviations. The parameters obtained by bootstrap analysis do not deviate
significantly from the model. Median, 5th and 95th percentiles in the VPC method mostly
were within the simulated 95% confidence interval. The obtained population
pharmacokinetic model, after additional optimization, can be used for individualization of
the tacrolimus dosing regimen in the population of liver transplant recipients., Takrolimus je imunosupresiv koji se primenjuje za prevenciju odbacivanja grafta
nakon transplantacije jetre. Uzak terapijski opseg i velika varijabilnost u farmakokinetici
ukazuju na neophodnost individualizacije terapije. Cilj istraživanja bio je razvoj i validacija
osnovnog farmakokinetičkog modela takrolimusa baziranog na podacima prikupljenim
tokom terapijskog praćenja leka. Studija je uključila 29 pacijenata sa transplantiranom
jetrom, praćenih na Klinici za gastroenterologiju i hepatologiju, Kliničkog centra Srbije.
Primenom NONMEM® programa analizirane su koncentracije takrolimusa izmerene u punoj
krvi (260), neposredno pre primene jutarnje doze (Ctrough). Farmakokinetika je opisana
jednoprostornim modelom sa resorpcijom i eliminacijom prvog reda. Interna validacija je
vršena primenom grafičke metode procene, metode umnožavanja podataka (bootstrap) i
vizuelne prediktivne provere (VPC). Procenjena tipična vrednost oralnog klirensa (CL/F)
iznosila je 30,4 L/h, dok je vrednost oralnog volumena distribucije bila 5770 L. Vrednost
konstante brzine resorpcije je fiksirana na 4,48 h-1 . Interindividualna varijabilnost je najbolje
opisana eksponencijalnim modelom, a rezidualna aditivnim modelom. Zabeležena je
interindividualna varijabilnost za CL/F od 38,2%. Predviđene individualne koncentracije
(IPRED) pokazuju bolje slaganje sa izmerenim vrednostima, nego populacione predviđene
vrednosti (PRED). Uslovni težinski reziduali (CWRES vs PRED, CWRES vs TIME) su većinom
raspoređeni između -2 i +2 standardne devijacije. Parametri dobijeni bootstrap analizom ne
odstupaju značajno od modela, dok su vrednosti medijane, 5. i 95. percentila u VPC metodi
uglavnom bile u okviru simuliranih 95% intervala pouzdanosti. Dobijeni populacioni
farmakokinetički model, može se nakon dodatne optimizacije, primeniti u svrhu
individualizacije režima doziranja takrolimusa u populaciji pacijenata sa transplantiranom
jetrom.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "A population pharmacokinetic model of tacrolimus in adult liver transplant recipients, Populacioni farmakokinetički model takrolimusa kod pacijenata sa transplantiranom jetrom",
volume = "72",
number = "4 suplement",
pages = "S298-S299",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4531"
}

Jovanović, M., Ćulafić, M., Pejić, N., Štulić, M., Kovačević, M., Vezmar-Kovačević, S., Miljković, B., Ćulafić, Đ.,& Vučićević, K.. (2022). A population pharmacokinetic model of tacrolimus in adult liver transplant recipients. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S298-S299.
https://hdl.handle.net/21.15107/rcub_farfar_4531

Jovanović M, Ćulafić M, Pejić N, Štulić M, Kovačević M, Vezmar-Kovačević S, Miljković B, Ćulafić Đ, Vučićević K. A population pharmacokinetic model of tacrolimus in adult liver transplant recipients. in Arhiv za farmaciju. 2022;72(4 suplement):S298-S299.
https://hdl.handle.net/21.15107/rcub_farfar_4531 .

Jovanović, Marija, Ćulafić, Milica, Pejić, Nina, Štulić, Miloš, Kovačević, Milena, Vezmar-Kovačević, Sandra, Miljković, Branislava, Ćulafić, Đorđe, Vučićević, Katarina, "A population pharmacokinetic model of tacrolimus in adult liver transplant recipients" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S298-S299,
https://hdl.handle.net/21.15107/rcub_farfar_4531 .

TY  - CONF
AU  - Jovanović, Nina
AU  - Marković, Aleksandra
AU  - Miljković, Branislava
AU  - Vezmar-Kovačević, Sandra
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4527
AB  - Drug interactions are classified as quantitative and/or qualitative alterations in the
effects of one drug in the presence of another one. Bipolar disorder is an affective disorder
characterized by manic and depressive episodes and often requires more than one drug in its
treatment. In patients with comorbidities higher prevalence of clinically significant
interactions could be expected. The aim was to evaluate clinically significant drug
interactions in patients with bipolar disorder and determine whether patients’
characteristics such as age, number of comorbidities and polypharmacy are related with
their appearance. A retrospective study included 50 patients treated at the Institute of
mental health in Belgrade. Data were obtained from patients’ medical documentation.
Epocrates® database was used to identify potential drug interactions. SPSS® software was
used for statistical analysis. Patients’ average age was 46.19 ± 11.49. The average number of
drugs in therapy was 6.46±2.58 per patient. Total of 549 interactions were detected,
approximately 10.98±5.97 per patient. Most interactions (59.2%) demanded
monitoring/modification of therapy. Caution was advised in 28.78% of interactions while
11.66% of them suggested use of an alternative treatment. Only 0.36% drug interactions
were classified as contraindicated. A positive correlation between the total number of used
drugs and number of drug interactions is shown (p<0.001), as well as the patients’ age and
number of drug interactions (p<0.05). The results show a high prevalence of interactions in
the examined population which implies the importance of monitoring in order to secure
patients’ safety and avoid adverse effects.
AB  - Interakcije lekova predstavljaju kvalitativne i/ili kvantitativne promene delovanja
jednog leka u prisustvu drugog. Bipolarni poremećaj je afektivni poremećaj koji karakterišu
manične i depresivne epizode pa se u terapiji često primenjuje više od jednog leka. U
prisustvu pridruženih bolesti ukupan broj lekova u terapiji znatno raste, pa se može
očekivati visoka prevalenca klinički značajnih interakcija. Cilj istraživanja je procena
potencijalno klinički značajnih interakcija lekova kod pacijenata sa afektivnim bipolarnim
poremećajima. Takođe je ispitano da li karakteristike poput starosti, broja komorbiditeta,
polifarmacije utiču na ispoljavanje interakcija. Sprovedeno je retrospektivno istraživanje na
populaciji od 50 pacijenata lečenih na Institutu za mentalno zdravlje u Beogradu. Podaci su
prikupljeni iz medicinske dokumentacije pacijenata. Za analizu potencijalnih interakcije
korišćena je Epocrates ® baza podataka. Dobijeni rezultati obrađeni su pomoću SPSS®
programa. Prosečna starost pacijenta bila je 46,19 ± 11,49 godina, a prosečan broj lekova u
terapiji iznosio je 6,46 ± 2,58. Detektovano je 549 interakcija, dok je prosek po pacijentu bio
10,98 ± 5,97. U većini slučajeva je bilo potrebno praćenje/modifikacija terapije (59,2%),
oprez je bio potreban kod 28,78% interakcija dok je u 11,66% slučajeva bilo potrebno izbeći
kombinaciju ispitivanih lekova i uvesti alternativnu terapiju. Udeo interakcija lekova čija je
primena kontraindikovana iznosio je 0,36%. Analiza je pokazala statistički uticaj broja
lekova u terapiji na broj interakcija (p<0,001), kao i starosti pacijenta na broj interakcija
(p<0,05). Dobijeni rezultati ukazuju na postojanje velikog broja klinički značajnih interakcija
u ispitivanoj populaciji i na značaj procene interakcija u prisustvu komorbiditeta kako bi se
osigurala bezbednost pacijenta i izbegli neželjeni efekti.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - An overview of drug interactions in patients with affective bipolar disorder
T1  - Pregled interakcija lekova kod pacijenata sa afektivnim bipolarnim poremećajem
VL  - 72
IS  - 4 suplement
SP  - S272
EP  - S273
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4527
ER  - 

@conference{
author = "Jovanović, Nina and Marković, Aleksandra and Miljković, Branislava and Vezmar-Kovačević, Sandra",
year = "2022",
abstract = "Drug interactions are classified as quantitative and/or qualitative alterations in the
effects of one drug in the presence of another one. Bipolar disorder is an affective disorder
characterized by manic and depressive episodes and often requires more than one drug in its
treatment. In patients with comorbidities higher prevalence of clinically significant
interactions could be expected. The aim was to evaluate clinically significant drug
interactions in patients with bipolar disorder and determine whether patients’
characteristics such as age, number of comorbidities and polypharmacy are related with
their appearance. A retrospective study included 50 patients treated at the Institute of
mental health in Belgrade. Data were obtained from patients’ medical documentation.
Epocrates® database was used to identify potential drug interactions. SPSS® software was
used for statistical analysis. Patients’ average age was 46.19 ± 11.49. The average number of
drugs in therapy was 6.46±2.58 per patient. Total of 549 interactions were detected,
approximately 10.98±5.97 per patient. Most interactions (59.2%) demanded
monitoring/modification of therapy. Caution was advised in 28.78% of interactions while
11.66% of them suggested use of an alternative treatment. Only 0.36% drug interactions
were classified as contraindicated. A positive correlation between the total number of used
drugs and number of drug interactions is shown (p<0.001), as well as the patients’ age and
number of drug interactions (p<0.05). The results show a high prevalence of interactions in
the examined population which implies the importance of monitoring in order to secure
patients’ safety and avoid adverse effects., Interakcije lekova predstavljaju kvalitativne i/ili kvantitativne promene delovanja
jednog leka u prisustvu drugog. Bipolarni poremećaj je afektivni poremećaj koji karakterišu
manične i depresivne epizode pa se u terapiji često primenjuje više od jednog leka. U
prisustvu pridruženih bolesti ukupan broj lekova u terapiji znatno raste, pa se može
očekivati visoka prevalenca klinički značajnih interakcija. Cilj istraživanja je procena
potencijalno klinički značajnih interakcija lekova kod pacijenata sa afektivnim bipolarnim
poremećajima. Takođe je ispitano da li karakteristike poput starosti, broja komorbiditeta,
polifarmacije utiču na ispoljavanje interakcija. Sprovedeno je retrospektivno istraživanje na
populaciji od 50 pacijenata lečenih na Institutu za mentalno zdravlje u Beogradu. Podaci su
prikupljeni iz medicinske dokumentacije pacijenata. Za analizu potencijalnih interakcije
korišćena je Epocrates ® baza podataka. Dobijeni rezultati obrađeni su pomoću SPSS®
programa. Prosečna starost pacijenta bila je 46,19 ± 11,49 godina, a prosečan broj lekova u
terapiji iznosio je 6,46 ± 2,58. Detektovano je 549 interakcija, dok je prosek po pacijentu bio
10,98 ± 5,97. U većini slučajeva je bilo potrebno praćenje/modifikacija terapije (59,2%),
oprez je bio potreban kod 28,78% interakcija dok je u 11,66% slučajeva bilo potrebno izbeći
kombinaciju ispitivanih lekova i uvesti alternativnu terapiju. Udeo interakcija lekova čija je
primena kontraindikovana iznosio je 0,36%. Analiza je pokazala statistički uticaj broja
lekova u terapiji na broj interakcija (p<0,001), kao i starosti pacijenta na broj interakcija
(p<0,05). Dobijeni rezultati ukazuju na postojanje velikog broja klinički značajnih interakcija
u ispitivanoj populaciji i na značaj procene interakcija u prisustvu komorbiditeta kako bi se
osigurala bezbednost pacijenta i izbegli neželjeni efekti.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "An overview of drug interactions in patients with affective bipolar disorder, Pregled interakcija lekova kod pacijenata sa afektivnim bipolarnim poremećajem",
volume = "72",
number = "4 suplement",
pages = "S272-S273",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4527"
}

Jovanović, N., Marković, A., Miljković, B.,& Vezmar-Kovačević, S.. (2022). An overview of drug interactions in patients with affective bipolar disorder. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S272-S273.
https://hdl.handle.net/21.15107/rcub_farfar_4527

Jovanović N, Marković A, Miljković B, Vezmar-Kovačević S. An overview of drug interactions in patients with affective bipolar disorder. in Arhiv za farmaciju. 2022;72(4 suplement):S272-S273.
https://hdl.handle.net/21.15107/rcub_farfar_4527 .

Jovanović, Nina, Marković, Aleksandra, Miljković, Branislava, Vezmar-Kovačević, Sandra, "An overview of drug interactions in patients with affective bipolar disorder" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S272-S273,
https://hdl.handle.net/21.15107/rcub_farfar_4527 .

TY  - CONF
AU  - Drndarević, Aneta
AU  - Draganov, Ivana
AU  - Miljković, Branislava
AU  - Davidović, Aleksandar
AU  - Cvijanović, Dane
AU  - Savković, Tatjana
AU  - Vezmar-Kovačević, Sandra
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4506
AB  - Clinically significant drug-drug interactions (DDIs) are expected in patients with
cardiovascular diseases due to the number of drugs in therapy. The aim of the research was
to analyze DDIs during treatment which preceeded the admission to the cardiology
department. In the cardiology department of the Clinical Hospital Center Zvezdara, the
treatment of patients with ≥2 drugs before admission was analyzed. DDIs were identified
using the Lexicomp database (Lexi-Interact). Data were analyzed descriptively and with
linear regression analysis. During research, out of 132 participants 88.6% had ≥1, while
41.7% had ≥5 DDIs. The total number of DDIs was 648 (median 3, range 0-19). Men
constituted 64.4% of the population, with a median age of 70 years (32-90). Patients had 4
diagnoses (1-13) and 6 medications on admission (2-15). In 3.8% of patients,
contraindicated DDIs of anticholinergics were observed, 23.5% had DDIs that required
caution or a change in therapy, while interactions requiring follow-up were observed in
86.4% of patients. Angiotensin-converting enzyme inhibitors (30.4%), acetylsalicylic acid
(26.6%) and loop diuretics (16.5%) were most frequently involved in DDIs, while the most
common adverse events could be renal failure (21.5%), hypotension 19.7%) and bleeding
(13.7%). The number of drugs in therapy was a predictor of DDIs (p <0.001). Patients with
cardiovascular disease are often exposed to polypharmacy and consequently DDIs.
Cardiovascular drugs were most frequently involved in DDIs, but contraindicated DDIs were
present in anticholinergic drugs. In patients with cardiovascular diseases, monitoring of
renal function, hypotension and bleeding is required.
AB  - Klinički značajne interakcije (KZI) očekuju se kod pacijenata sa kardiovaskularnim
bolestima usled većeg broja lekova u terapiji. Cilj istraživanja je bio da se identifikuju i
analiziraju KZI pacijenata koje su prethodile prijemu na odeljenje kardiologije. U Kliničko-
bolničkom centru Zvezdara, na odeljenju kardiologije, analizirana je terapija pacijenata sa ≥2
leka pre prijema. KZI su identifikovane upotrebom baze Lexicomp (Lexi-Interact). Podaci su
analizirani deskriptivno i primenom linearne regresione analize. Od 132 učesnika u
istraživanju 88,6% je imalo ≥1, dok je 41,7% imalo ≥5 KZI. Ukupan broj KZI bio je 648
(medijana 3, opseg 0-19). U populaciji je bilo 64,4% muškaraca medijane starosti 70 godina
(32-90). Pacijenti su imali 4 dijagnoze (1-13) i 6 lekova na prijemu (2-15). Kod 3,8%
pacijenata utvrđene su KZI antiholinergika koje se smatraju kontraindikovanim. Približno
jedna četvrtina pacijenata (23,5%) je imala KZI koja zahteva oprez ili izmenu u terapiji dok
su kod 86,4% pacijenata uočene interakcije koje zahtevaju praćenje ishoda. Najčešće su u KZI
stupali inhibitori angiotenzin-konvertujućeg enzima (30,4%), acetilsalicilna kiselina (26,6%)
i diuretici petlje (16,5%) dok su najčešći neželjeni ishodi mogli biti bubrežna insuficijencija
(21,5%), hipotenzija (19,7%) i krvarenje (13,7%). Broj lekova u terapiji bio je prediktor za
KZI (p<0,001). Pacijenti sa kardiovaskularnim bolestima su često izloženi polifarmaciji i
posledično većem broju KZI. U KZI su najčešće stupali lekovi u terapiji kardiovaskularnih
bolesti ali su kontraindikovane KZI bile zastupljene kod antiholinergičkih lekova. Kod
pacijenata sa kardiovaskularnim bolestima potrebno je praćenje renalne funkcije,
hipotenzije i krvarenja.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Clinically significant drug-drug interactions in the treatment of cardiovascular diseases on hospital admission
T1  - Pregled klinički značajnih interakcija u terapiji kardiovaskularnih bolesti kod pacijenata na prijemu u bolnicu
VL  - 72
IS  - 4 suplement
SP  - S223
EP  - S224
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4506
ER  - 

@conference{
author = "Drndarević, Aneta and Draganov, Ivana and Miljković, Branislava and Davidović, Aleksandar and Cvijanović, Dane and Savković, Tatjana and Vezmar-Kovačević, Sandra",
year = "2022",
abstract = "Clinically significant drug-drug interactions (DDIs) are expected in patients with
cardiovascular diseases due to the number of drugs in therapy. The aim of the research was
to analyze DDIs during treatment which preceeded the admission to the cardiology
department. In the cardiology department of the Clinical Hospital Center Zvezdara, the
treatment of patients with ≥2 drugs before admission was analyzed. DDIs were identified
using the Lexicomp database (Lexi-Interact). Data were analyzed descriptively and with
linear regression analysis. During research, out of 132 participants 88.6% had ≥1, while
41.7% had ≥5 DDIs. The total number of DDIs was 648 (median 3, range 0-19). Men
constituted 64.4% of the population, with a median age of 70 years (32-90). Patients had 4
diagnoses (1-13) and 6 medications on admission (2-15). In 3.8% of patients,
contraindicated DDIs of anticholinergics were observed, 23.5% had DDIs that required
caution or a change in therapy, while interactions requiring follow-up were observed in
86.4% of patients. Angiotensin-converting enzyme inhibitors (30.4%), acetylsalicylic acid
(26.6%) and loop diuretics (16.5%) were most frequently involved in DDIs, while the most
common adverse events could be renal failure (21.5%), hypotension 19.7%) and bleeding
(13.7%). The number of drugs in therapy was a predictor of DDIs (p <0.001). Patients with
cardiovascular disease are often exposed to polypharmacy and consequently DDIs.
Cardiovascular drugs were most frequently involved in DDIs, but contraindicated DDIs were
present in anticholinergic drugs. In patients with cardiovascular diseases, monitoring of
renal function, hypotension and bleeding is required., Klinički značajne interakcije (KZI) očekuju se kod pacijenata sa kardiovaskularnim
bolestima usled većeg broja lekova u terapiji. Cilj istraživanja je bio da se identifikuju i
analiziraju KZI pacijenata koje su prethodile prijemu na odeljenje kardiologije. U Kliničko-
bolničkom centru Zvezdara, na odeljenju kardiologije, analizirana je terapija pacijenata sa ≥2
leka pre prijema. KZI su identifikovane upotrebom baze Lexicomp (Lexi-Interact). Podaci su
analizirani deskriptivno i primenom linearne regresione analize. Od 132 učesnika u
istraživanju 88,6% je imalo ≥1, dok je 41,7% imalo ≥5 KZI. Ukupan broj KZI bio je 648
(medijana 3, opseg 0-19). U populaciji je bilo 64,4% muškaraca medijane starosti 70 godina
(32-90). Pacijenti su imali 4 dijagnoze (1-13) i 6 lekova na prijemu (2-15). Kod 3,8%
pacijenata utvrđene su KZI antiholinergika koje se smatraju kontraindikovanim. Približno
jedna četvrtina pacijenata (23,5%) je imala KZI koja zahteva oprez ili izmenu u terapiji dok
su kod 86,4% pacijenata uočene interakcije koje zahtevaju praćenje ishoda. Najčešće su u KZI
stupali inhibitori angiotenzin-konvertujućeg enzima (30,4%), acetilsalicilna kiselina (26,6%)
i diuretici petlje (16,5%) dok su najčešći neželjeni ishodi mogli biti bubrežna insuficijencija
(21,5%), hipotenzija (19,7%) i krvarenje (13,7%). Broj lekova u terapiji bio je prediktor za
KZI (p<0,001). Pacijenti sa kardiovaskularnim bolestima su često izloženi polifarmaciji i
posledično većem broju KZI. U KZI su najčešće stupali lekovi u terapiji kardiovaskularnih
bolesti ali su kontraindikovane KZI bile zastupljene kod antiholinergičkih lekova. Kod
pacijenata sa kardiovaskularnim bolestima potrebno je praćenje renalne funkcije,
hipotenzije i krvarenja.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Clinically significant drug-drug interactions in the treatment of cardiovascular diseases on hospital admission, Pregled klinički značajnih interakcija u terapiji kardiovaskularnih bolesti kod pacijenata na prijemu u bolnicu",
volume = "72",
number = "4 suplement",
pages = "S223-S224",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4506"
}

Drndarević, A., Draganov, I., Miljković, B., Davidović, A., Cvijanović, D., Savković, T.,& Vezmar-Kovačević, S.. (2022). Clinically significant drug-drug interactions in the treatment of cardiovascular diseases on hospital admission. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S223-S224.
https://hdl.handle.net/21.15107/rcub_farfar_4506

Drndarević A, Draganov I, Miljković B, Davidović A, Cvijanović D, Savković T, Vezmar-Kovačević S. Clinically significant drug-drug interactions in the treatment of cardiovascular diseases on hospital admission. in Arhiv za farmaciju. 2022;72(4 suplement):S223-S224.
https://hdl.handle.net/21.15107/rcub_farfar_4506 .

Drndarević, Aneta, Draganov, Ivana, Miljković, Branislava, Davidović, Aleksandar, Cvijanović, Dane, Savković, Tatjana, Vezmar-Kovačević, Sandra, "Clinically significant drug-drug interactions in the treatment of cardiovascular diseases on hospital admission" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S223-S224,
https://hdl.handle.net/21.15107/rcub_farfar_4506 .

TY  - CONF
AU  - Draganov, Ivana
AU  - Drndarević, Aneta
AU  - Miljković, Branislava
AU  - Davidović, Aleksandar
AU  - Cvijanović, Dane
AU  - Savković, Tatjana
AU  - Vezmar-Kovačević, Sandra
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4501
AB  - In patients with cardiovascular diseases drug-related problems (DRPs) can be
associated with hospitalization or rehospitalization. The aim of the research was to analyse
DRPs in the cardiology department on admission to the hospital. All patient records on
admission to the cardiology department of the Clinical Hospital Center Zvezdara during
2018., were analyzed. Demographic and treatment data of the patient before admission to
the hospital were collected. DRPs associated with pre-hospital treatment were identified and
classified according to the PCNE (Pharmaceutical Care Network Europe, version 9.1)
classification. DRPs were also evaluated as cause of the patient's hospitalization. Data were
analyzed descriptively and with linear regression analysis. During the research period, 143
patients were admitted to the cardiology department, with an average age of 69.75 ± 10.11
years, of which 65.7% were male. Patients had an average of 4.36±2.13 diagnoses and
5.24±3.39 medications on admission. We observed 1.85±1.37 DRPs per patient (range 0-5).
The most common DRP (75.6%) was lack of ≥1 drugs in the therapy preceding the
admission, most often statins (30.1% of patients), beta-blockers (25.9%), angiotensin-
converting enzyme inhibitors (17.5%) and antiarrhythmics/anticoagulants (12.6%). In 96
patients (67.1%) the identified DRPs could be associated with the cause of hospitalization.
Atrial fibrillation was the predictor of the number of DRPs in patients (p <0.001). In most
cardiovascular patients, the cause of hospitalization could be associated with DRPs before
admission. Incomplete therapy of the patient was commonly observed, the cause of which
may be inadequate prescribing or lack of adherence of the patient.
AB  - Pacijenti sa kardiovaskularnim bolestima susreću se sa brojnim problemima u terapiji
od kojih pojedini mogu biti uzrok hospitalizacije ili rehospitalizacije. Cilj istraživanja je bio da
se prikaže analiza terapijskih problema pacijenata na odeljenju kardiologije, prilikom
prijema u bolnicu. Analizirani su kartoni svih pacijenata primljenih na odeljenje kardiologije,
Kliničko-bolničkog centra Zvezdara tokom 2018. godine. Prikupljeni su demografski i podaci
o celokupnoj terapiji pacijenta pre prijema u bolnicu. Identifikovani su problemi u vezi sa
terapijom pre prijema u bolnicu i klasifikovani su prema PCNE (Pharmaceutical Care
Network Europe, verzija 9.1) klasifikaciji. Takođe, procenjeno je da li problemi u vezi sa
terapijom mogu biti uzrok hospitalizacije pacijenta. Podaci su analizirani deskriptivno i
primenom linearne regresione analize. U periodu istraživanja 143 pacijenta je primljeno na
odeljenje kardiologije, prosečne starosti 69,75±10,11 godina, od kojih je 65,7% bilo muškog
pola. Pacijenti su u proseku imali 4,36±2,13 dijagnoze i 5,24±3,39 lekova na prijemu.
Utvrđeno je prisustvo 1,85±1,37 terapijskih problema po pacijentu (opseg 0-5). Najčešći
terapijski problem (75,6%) bio je nedostatak ≥1 leka u terapiji i to najčešće statina (30,1%
pacijenata), beta-blokatora (25,9%), inhibitora angiotenzin-konvertujućeg enzima (17,5%) i
antiaritmika/anitkoagulanasa (12,6%). Kod 96 pacijenata (67,1%) su identifikovani
terapijski problemi dovedeni u vezu sa uzrokom hospitalizacije. Prediktivni faktor za broj
terapijskih problema kod pacijenata je bilo prisustvo atrijalne fibrilacije u anamnezi
(p<0,001). Uzrok hospitalizacije pacijenata sa kardiovaskularnim bolestima se često može
povezati sa problemima u terapiji pre prijema. Najčešće se uočava nepotpuna terapija
pacijenta čiji uzrok može biti neodgovarajuće propisivanje ili nedostatak adherence
pacijenta.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Drug-related problems of patients with cardiovascular diseases on hospital admission
T1  - Terapijski problemi pacijenata sa kardiovaskularnim bolestima na prijemu u bolnicu
VL  - 72
IS  - 4 suplement
SP  - S221
EP  - S222
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4501
ER  - 

@conference{
author = "Draganov, Ivana and Drndarević, Aneta and Miljković, Branislava and Davidović, Aleksandar and Cvijanović, Dane and Savković, Tatjana and Vezmar-Kovačević, Sandra",
year = "2022",
abstract = "In patients with cardiovascular diseases drug-related problems (DRPs) can be
associated with hospitalization or rehospitalization. The aim of the research was to analyse
DRPs in the cardiology department on admission to the hospital. All patient records on
admission to the cardiology department of the Clinical Hospital Center Zvezdara during
2018., were analyzed. Demographic and treatment data of the patient before admission to
the hospital were collected. DRPs associated with pre-hospital treatment were identified and
classified according to the PCNE (Pharmaceutical Care Network Europe, version 9.1)
classification. DRPs were also evaluated as cause of the patient's hospitalization. Data were
analyzed descriptively and with linear regression analysis. During the research period, 143
patients were admitted to the cardiology department, with an average age of 69.75 ± 10.11
years, of which 65.7% were male. Patients had an average of 4.36±2.13 diagnoses and
5.24±3.39 medications on admission. We observed 1.85±1.37 DRPs per patient (range 0-5).
The most common DRP (75.6%) was lack of ≥1 drugs in the therapy preceding the
admission, most often statins (30.1% of patients), beta-blockers (25.9%), angiotensin-
converting enzyme inhibitors (17.5%) and antiarrhythmics/anticoagulants (12.6%). In 96
patients (67.1%) the identified DRPs could be associated with the cause of hospitalization.
Atrial fibrillation was the predictor of the number of DRPs in patients (p <0.001). In most
cardiovascular patients, the cause of hospitalization could be associated with DRPs before
admission. Incomplete therapy of the patient was commonly observed, the cause of which
may be inadequate prescribing or lack of adherence of the patient., Pacijenti sa kardiovaskularnim bolestima susreću se sa brojnim problemima u terapiji
od kojih pojedini mogu biti uzrok hospitalizacije ili rehospitalizacije. Cilj istraživanja je bio da
se prikaže analiza terapijskih problema pacijenata na odeljenju kardiologije, prilikom
prijema u bolnicu. Analizirani su kartoni svih pacijenata primljenih na odeljenje kardiologije,
Kliničko-bolničkog centra Zvezdara tokom 2018. godine. Prikupljeni su demografski i podaci
o celokupnoj terapiji pacijenta pre prijema u bolnicu. Identifikovani su problemi u vezi sa
terapijom pre prijema u bolnicu i klasifikovani su prema PCNE (Pharmaceutical Care
Network Europe, verzija 9.1) klasifikaciji. Takođe, procenjeno je da li problemi u vezi sa
terapijom mogu biti uzrok hospitalizacije pacijenta. Podaci su analizirani deskriptivno i
primenom linearne regresione analize. U periodu istraživanja 143 pacijenta je primljeno na
odeljenje kardiologije, prosečne starosti 69,75±10,11 godina, od kojih je 65,7% bilo muškog
pola. Pacijenti su u proseku imali 4,36±2,13 dijagnoze i 5,24±3,39 lekova na prijemu.
Utvrđeno je prisustvo 1,85±1,37 terapijskih problema po pacijentu (opseg 0-5). Najčešći
terapijski problem (75,6%) bio je nedostatak ≥1 leka u terapiji i to najčešće statina (30,1%
pacijenata), beta-blokatora (25,9%), inhibitora angiotenzin-konvertujućeg enzima (17,5%) i
antiaritmika/anitkoagulanasa (12,6%). Kod 96 pacijenata (67,1%) su identifikovani
terapijski problemi dovedeni u vezu sa uzrokom hospitalizacije. Prediktivni faktor za broj
terapijskih problema kod pacijenata je bilo prisustvo atrijalne fibrilacije u anamnezi
(p<0,001). Uzrok hospitalizacije pacijenata sa kardiovaskularnim bolestima se često može
povezati sa problemima u terapiji pre prijema. Najčešće se uočava nepotpuna terapija
pacijenta čiji uzrok može biti neodgovarajuće propisivanje ili nedostatak adherence
pacijenta.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Drug-related problems of patients with cardiovascular diseases on hospital admission, Terapijski problemi pacijenata sa kardiovaskularnim bolestima na prijemu u bolnicu",
volume = "72",
number = "4 suplement",
pages = "S221-S222",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4501"
}

Draganov, I., Drndarević, A., Miljković, B., Davidović, A., Cvijanović, D., Savković, T.,& Vezmar-Kovačević, S.. (2022). Drug-related problems of patients with cardiovascular diseases on hospital admission. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S221-S222.
https://hdl.handle.net/21.15107/rcub_farfar_4501

Draganov I, Drndarević A, Miljković B, Davidović A, Cvijanović D, Savković T, Vezmar-Kovačević S. Drug-related problems of patients with cardiovascular diseases on hospital admission. in Arhiv za farmaciju. 2022;72(4 suplement):S221-S222.
https://hdl.handle.net/21.15107/rcub_farfar_4501 .

Draganov, Ivana, Drndarević, Aneta, Miljković, Branislava, Davidović, Aleksandar, Cvijanović, Dane, Savković, Tatjana, Vezmar-Kovačević, Sandra, "Drug-related problems of patients with cardiovascular diseases on hospital admission" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S221-S222,
https://hdl.handle.net/21.15107/rcub_farfar_4501 .

TY  - CONF
AU  - Jovanović, Marija
AU  - Ćulafić, Milica
AU  - Pejić, Nina
AU  - Štulić, Miloš
AU  - Kovačević, Milena
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
AU  - Vučićević, Katarina
AU  - Ćulafić, Đorđe
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4395
AB  - Takrolimus je imunosupresiv koji se primenjuje za prevenciju odbacivanja grafta
nakon transplantacije jetre. Uzak terapijski opseg i velika varijabilnost u farmakokinetici
ukazuju na neophodnost individualizacije terapije. Cilj istraživanja bio je razvoj i validacija
osnovnog farmakokinetičkog modela takrolimusa baziranog na podacima prikupljenim
tokom terapijskog praćenja leka. Studija je uključila 29 pacijenata sa transplantiranom
jetrom, praćenih na Klinici za gastroenterologiju i hepatologiju, Kliničkog centra Srbije.
Primenom NONMEM® programa analizirane su koncentracije takrolimusa izmerene u punoj
krvi (260), neposredno pre primene jutarnje doze (Ctrough). Farmakokinetika je opisana
jednoprostornim modelom sa resorpcijom i eliminacijom prvog reda. Interna validacija je
vršena primenom grafičke metode procene, metode umnožavanja podataka (bootstrap) i
vizuelne prediktivne provere (VPC). Procenjena tipična vrednost oralnog klirensa (CL/F)
iznosila je 30,4 L/h, dok je vrednost oralnog volumena distribucije bila 5770 L. Vrednost
konstante brzine resorpcije je fiksirana na 4,48 h-1 . Interindividualna varijabilnost je najbolje
opisana eksponencijalnim modelom, a rezidualna aditivnim modelom. Zabeležena je
interindividualna varijabilnost za CL/F od 38,2%. Predviđene individualne koncentracije
(IPRED) pokazuju bolje slaganje sa izmerenim vrednostima, nego populacione predviđene
vrednosti (PRED). Uslovni težinski reziduali (CWRES vs PRED, CWRES vs TIME) su većinom
raspoređeni između -2 i +2 standardne devijacije. Parametri dobijeni bootstrap analizom ne
odstupaju značajno od modela, dok su vrednosti medijane, 5. i 95. percentila u VPC metodi
uglavnom bile u okviru simuliranih 95% intervala pouzdanosti. Dobijeni populacioni
farmakokinetički model, može se nakon dodatne optimizacije, primeniti u svrhu
individualizacije režima doziranja takrolimusa u populaciji pacijenata sa transplantiranom
jetrom.
AB  - Tacrolimus is an immunosuppressant used to prevent graft rejection after liver transplantation. The narrow therapeutic range and great variability in pharmacokinetics indicate the need for therapy individualization. The aim of the study was to develop and validate the base pharmacokinetic model of tacrolimus using data collected during therapeutic drug monitoring. The study included 29 liver transplant recipients followed up at Clinic for Gastroenterology and Hepatology, Clinical Center of Serbia. Using the NONMEM® program, we analyzed tacrolimus concentrations (Ctrough) measured in whole blood (260). Pharmacokinetics have been described as one-compartment model with first- order absorption and elimination. Internal validation was performed using graphical assessment, bootstrap method and visual predictive check (VPC). Typical value of oral clearance (CL/F) was 30.4 L/h, while value of oral volume of distribution was 5770 L. The value of the absorption rate constant was fixed at 4.48 h-1 . Interindividual variability was best described by the exponential model, and residual by the additive model. Interindividual variability for CL/F was 38.2%. Individual predicted concentrations (IPRED) showed better agreement with the measured values than population predicted values (PRED). Conditional weighted residuals (CWRES vs PRED, CWRES vs TIME) were mostly between -2 and +2 standard deviations. The parameters obtained by bootstrap analysis do not deviate significantly from the model. Median, 5th and 95th percentiles in the VPC method mostly were within the simulated 95% confidence interval. The obtained population pharmacokinetic model, after additional optimization, can be used for individualization of the tacrolimus dosing regimen in the population of liver transplant recipients.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Populacioni farmakokinetički model takrolimusa kod pacijenata sa transplantiranom jetrom
T1  - A population pharmacokinetic model of tacrolimus in adult liver transplant recipients
VL  - 72
IS  - 4 Suplement
SP  - S298
EP  - S299
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4395
ER  - 

@conference{
author = "Jovanović, Marija and Ćulafić, Milica and Pejić, Nina and Štulić, Miloš and Kovačević, Milena and Vezmar-Kovačević, Sandra and Miljković, Branislava and Vučićević, Katarina and Ćulafić, Đorđe",
year = "2022",
abstract = "Takrolimus je imunosupresiv koji se primenjuje za prevenciju odbacivanja grafta
nakon transplantacije jetre. Uzak terapijski opseg i velika varijabilnost u farmakokinetici
ukazuju na neophodnost individualizacije terapije. Cilj istraživanja bio je razvoj i validacija
osnovnog farmakokinetičkog modela takrolimusa baziranog na podacima prikupljenim
tokom terapijskog praćenja leka. Studija je uključila 29 pacijenata sa transplantiranom
jetrom, praćenih na Klinici za gastroenterologiju i hepatologiju, Kliničkog centra Srbije.
Primenom NONMEM® programa analizirane su koncentracije takrolimusa izmerene u punoj
krvi (260), neposredno pre primene jutarnje doze (Ctrough). Farmakokinetika je opisana
jednoprostornim modelom sa resorpcijom i eliminacijom prvog reda. Interna validacija je
vršena primenom grafičke metode procene, metode umnožavanja podataka (bootstrap) i
vizuelne prediktivne provere (VPC). Procenjena tipična vrednost oralnog klirensa (CL/F)
iznosila je 30,4 L/h, dok je vrednost oralnog volumena distribucije bila 5770 L. Vrednost
konstante brzine resorpcije je fiksirana na 4,48 h-1 . Interindividualna varijabilnost je najbolje
opisana eksponencijalnim modelom, a rezidualna aditivnim modelom. Zabeležena je
interindividualna varijabilnost za CL/F od 38,2%. Predviđene individualne koncentracije
(IPRED) pokazuju bolje slaganje sa izmerenim vrednostima, nego populacione predviđene
vrednosti (PRED). Uslovni težinski reziduali (CWRES vs PRED, CWRES vs TIME) su većinom
raspoređeni između -2 i +2 standardne devijacije. Parametri dobijeni bootstrap analizom ne
odstupaju značajno od modela, dok su vrednosti medijane, 5. i 95. percentila u VPC metodi
uglavnom bile u okviru simuliranih 95% intervala pouzdanosti. Dobijeni populacioni
farmakokinetički model, može se nakon dodatne optimizacije, primeniti u svrhu
individualizacije režima doziranja takrolimusa u populaciji pacijenata sa transplantiranom
jetrom., Tacrolimus is an immunosuppressant used to prevent graft rejection after liver transplantation. The narrow therapeutic range and great variability in pharmacokinetics indicate the need for therapy individualization. The aim of the study was to develop and validate the base pharmacokinetic model of tacrolimus using data collected during therapeutic drug monitoring. The study included 29 liver transplant recipients followed up at Clinic for Gastroenterology and Hepatology, Clinical Center of Serbia. Using the NONMEM® program, we analyzed tacrolimus concentrations (Ctrough) measured in whole blood (260). Pharmacokinetics have been described as one-compartment model with first- order absorption and elimination. Internal validation was performed using graphical assessment, bootstrap method and visual predictive check (VPC). Typical value of oral clearance (CL/F) was 30.4 L/h, while value of oral volume of distribution was 5770 L. The value of the absorption rate constant was fixed at 4.48 h-1 . Interindividual variability was best described by the exponential model, and residual by the additive model. Interindividual variability for CL/F was 38.2%. Individual predicted concentrations (IPRED) showed better agreement with the measured values than population predicted values (PRED). Conditional weighted residuals (CWRES vs PRED, CWRES vs TIME) were mostly between -2 and +2 standard deviations. The parameters obtained by bootstrap analysis do not deviate significantly from the model. Median, 5th and 95th percentiles in the VPC method mostly were within the simulated 95% confidence interval. The obtained population pharmacokinetic model, after additional optimization, can be used for individualization of the tacrolimus dosing regimen in the population of liver transplant recipients.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Populacioni farmakokinetički model takrolimusa kod pacijenata sa transplantiranom jetrom, A population pharmacokinetic model of tacrolimus in adult liver transplant recipients",
volume = "72",
number = "4 Suplement",
pages = "S298-S299",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4395"
}

Jovanović, M., Ćulafić, M., Pejić, N., Štulić, M., Kovačević, M., Vezmar-Kovačević, S., Miljković, B., Vučićević, K.,& Ćulafić, Đ.. (2022). Populacioni farmakokinetički model takrolimusa kod pacijenata sa transplantiranom jetrom. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 Suplement), S298-S299.
https://hdl.handle.net/21.15107/rcub_farfar_4395

Jovanović M, Ćulafić M, Pejić N, Štulić M, Kovačević M, Vezmar-Kovačević S, Miljković B, Vučićević K, Ćulafić Đ. Populacioni farmakokinetički model takrolimusa kod pacijenata sa transplantiranom jetrom. in Arhiv za farmaciju. 2022;72(4 Suplement):S298-S299.
https://hdl.handle.net/21.15107/rcub_farfar_4395 .

Jovanović, Marija, Ćulafić, Milica, Pejić, Nina, Štulić, Miloš, Kovačević, Milena, Vezmar-Kovačević, Sandra, Miljković, Branislava, Vučićević, Katarina, Ćulafić, Đorđe, "Populacioni farmakokinetički model takrolimusa kod pacijenata sa transplantiranom jetrom" in Arhiv za farmaciju, 72, no. 4 Suplement (2022):S298-S299,
https://hdl.handle.net/21.15107/rcub_farfar_4395 .

TY  - CONF
AU  - Damjanović, Maja
AU  - Kovačević, Milena
AU  - Musić, Nina
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4392
AB  - Kvalitet života je postao značajan aspekt praćenja ishoda terapije u istraživanjima i
svakodnevnoj praksi. Cilj istraživanja bila je procena kvaliteta života u odnosu na
karakteristike pacijenata ili terapije. U istraživanje su uključeni odrasli pacijenti (≥18
godina) sa najmanje jednom hroničnom bolešću. Za procenu kvaliteta života korišćen je
upitnik Euro‐Qol 5D‐5L. Statistička obrada podataka izvršena je primenom softvera SPSS (ver
27). Analizom su obuhvaćena 193 pacijenta, većinom žene (72%), prosečne starosti
53,7±17,3 godina (opseg 21-91). Polifarmacija (≥5 lekova) je bila prisutna kod 23,4%, dok je
19,2% pacijenata imalo polimorbidnost (≥3 bolesti). Najzastupljenije su bile bolesti
cirkulatornog sistema (54,9%), endokrine, bolesti ishrane i metabolizma (36,3%) i
muskuloskeletnog sistema (20,2%). Dobru kontrolu bolesti prijavilo je 68,4% pacijenata.
Prosečna vrednost QoL iznosila je 71,1±18,6 (opseg 7-100). Određeni stepen problema sa
pokretljivošću prijavilo je 46,1%, brigom o sebi 5,7%, obavljanjem svakodnevnih aktivnosti
36,3%, bolom ili nelagodnošću 58%, prisustvom anksioznih ili depresivnih osećanja 46,9%.
Vrednost QoL bila je statistički značajno viša kod pacijenata koji su naveli da imaju dobru
kontrolu bolesti (p=0,006), dok je bila značajno niža kod pacijenata na polifarmaciji
(p<0,001) ili sa polimorbiditetima (p<0,001). Nije pokazana značajna korelacija vrednosti
QoL i dužine trajanja bolesti, niti starosti pacijenta. Od vrste zdravstvenog problema,
vrednost QoL razlikovala se značajno samo u odnosu na prisustvo oboljenja oka (p=0,024).
Značajan procenat pacijenata prijavio je uticaj hronične bolesti na različite dimenzije
kvaliteta života. Kvalitet života bio je dodatno niži kod pacijenata sa istovremeno prisutnim
većim brojem lekova u terapiji, većim brojem komorbiditeta, kao i sa oboljenjima oka.
AB  - Quality of life (QoL) has become an important aspect of the therapy outcomes
assessment in research and daily practice. The aim was to assess the quality of life in relation
to the characteristics of patients or therapy. The study included adult patients (≥18 years)
with at least one chronic disease. The Euro-Qol 5D-5L questionnaire was used to assess QoL.
Statistical analysis was performed using SPSS software (ver 27). The analysis included 193
patients, mostly women (72%), with mean age 53.7 ± 17.3 years (range 21-91).
Polypharmacy (≥5 drugs) was present in 23.4%, and polymorbidity (≥3 diseases) in 19.2%
of patients. The most common were diseases of the circulatory system (54.9%), endocrine,
nutritional or metabolic diseases (36.3%) and diseases of the musculoskeletal system
(20.2%). Good disease control was self-reported by 68.4%. The mean QoL value was
71.1±18.6 (range 7-100). A certain degree of mobility problems was reported by 46.1%, self-
care 5.7%, usual activities 36.3%, pain or discomfort 58%, anxiety or depressive feelings
46.9%. The QoL value was significantly higher in patients who stated good disease control
(p=0.006), while it was significantly lower in patients with polypharmacy or polymorbidities
(both p<0.001). No significant correlation was shown between QoL and disease duration or
patient age. The QoL value differed significantly only in relation to the presence of eye
diseases (p=0.024). A significant percentage of patients reported the impact of chronic
disease on various dimensions of QoL. The QoL was additionally lower in patients with
polypharmacy, polymorbidity, as well as with eye diseases.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Procena kvaliteta života kod pacijenata sa hroničnim bolestima
T1  - Evaluation of quality of life in chronic disease patients
VL  - 72
IS  - 4-suplement
SP  - 260
EP  - 261
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4392
ER  - 

@conference{
author = "Damjanović, Maja and Kovačević, Milena and Musić, Nina and Vezmar-Kovačević, Sandra and Miljković, Branislava",
year = "2022",
abstract = "Kvalitet života je postao značajan aspekt praćenja ishoda terapije u istraživanjima i
svakodnevnoj praksi. Cilj istraživanja bila je procena kvaliteta života u odnosu na
karakteristike pacijenata ili terapije. U istraživanje su uključeni odrasli pacijenti (≥18
godina) sa najmanje jednom hroničnom bolešću. Za procenu kvaliteta života korišćen je
upitnik Euro‐Qol 5D‐5L. Statistička obrada podataka izvršena je primenom softvera SPSS (ver
27). Analizom su obuhvaćena 193 pacijenta, većinom žene (72%), prosečne starosti
53,7±17,3 godina (opseg 21-91). Polifarmacija (≥5 lekova) je bila prisutna kod 23,4%, dok je
19,2% pacijenata imalo polimorbidnost (≥3 bolesti). Najzastupljenije su bile bolesti
cirkulatornog sistema (54,9%), endokrine, bolesti ishrane i metabolizma (36,3%) i
muskuloskeletnog sistema (20,2%). Dobru kontrolu bolesti prijavilo je 68,4% pacijenata.
Prosečna vrednost QoL iznosila je 71,1±18,6 (opseg 7-100). Određeni stepen problema sa
pokretljivošću prijavilo je 46,1%, brigom o sebi 5,7%, obavljanjem svakodnevnih aktivnosti
36,3%, bolom ili nelagodnošću 58%, prisustvom anksioznih ili depresivnih osećanja 46,9%.
Vrednost QoL bila je statistički značajno viša kod pacijenata koji su naveli da imaju dobru
kontrolu bolesti (p=0,006), dok je bila značajno niža kod pacijenata na polifarmaciji
(p<0,001) ili sa polimorbiditetima (p<0,001). Nije pokazana značajna korelacija vrednosti
QoL i dužine trajanja bolesti, niti starosti pacijenta. Od vrste zdravstvenog problema,
vrednost QoL razlikovala se značajno samo u odnosu na prisustvo oboljenja oka (p=0,024).
Značajan procenat pacijenata prijavio je uticaj hronične bolesti na različite dimenzije
kvaliteta života. Kvalitet života bio je dodatno niži kod pacijenata sa istovremeno prisutnim
većim brojem lekova u terapiji, većim brojem komorbiditeta, kao i sa oboljenjima oka., Quality of life (QoL) has become an important aspect of the therapy outcomes
assessment in research and daily practice. The aim was to assess the quality of life in relation
to the characteristics of patients or therapy. The study included adult patients (≥18 years)
with at least one chronic disease. The Euro-Qol 5D-5L questionnaire was used to assess QoL.
Statistical analysis was performed using SPSS software (ver 27). The analysis included 193
patients, mostly women (72%), with mean age 53.7 ± 17.3 years (range 21-91).
Polypharmacy (≥5 drugs) was present in 23.4%, and polymorbidity (≥3 diseases) in 19.2%
of patients. The most common were diseases of the circulatory system (54.9%), endocrine,
nutritional or metabolic diseases (36.3%) and diseases of the musculoskeletal system
(20.2%). Good disease control was self-reported by 68.4%. The mean QoL value was
71.1±18.6 (range 7-100). A certain degree of mobility problems was reported by 46.1%, self-
care 5.7%, usual activities 36.3%, pain or discomfort 58%, anxiety or depressive feelings
46.9%. The QoL value was significantly higher in patients who stated good disease control
(p=0.006), while it was significantly lower in patients with polypharmacy or polymorbidities
(both p<0.001). No significant correlation was shown between QoL and disease duration or
patient age. The QoL value differed significantly only in relation to the presence of eye
diseases (p=0.024). A significant percentage of patients reported the impact of chronic
disease on various dimensions of QoL. The QoL was additionally lower in patients with
polypharmacy, polymorbidity, as well as with eye diseases.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Procena kvaliteta života kod pacijenata sa hroničnim bolestima, Evaluation of quality of life in chronic disease patients",
volume = "72",
number = "4-suplement",
pages = "260-261",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4392"
}

Damjanović, M., Kovačević, M., Musić, N., Vezmar-Kovačević, S.,& Miljković, B.. (2022). Procena kvaliteta života kod pacijenata sa hroničnim bolestima. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4-suplement), 260-261.
https://hdl.handle.net/21.15107/rcub_farfar_4392

Damjanović M, Kovačević M, Musić N, Vezmar-Kovačević S, Miljković B. Procena kvaliteta života kod pacijenata sa hroničnim bolestima. in Arhiv za farmaciju. 2022;72(4-suplement):260-261.
https://hdl.handle.net/21.15107/rcub_farfar_4392 .

Damjanović, Maja, Kovačević, Milena, Musić, Nina, Vezmar-Kovačević, Sandra, Miljković, Branislava, "Procena kvaliteta života kod pacijenata sa hroničnim bolestima" in Arhiv za farmaciju, 72, no. 4-suplement (2022):260-261,
https://hdl.handle.net/21.15107/rcub_farfar_4392 .

TY  - CONF
AU  - Marković, Aleksandra
AU  - Kovačević, Milena
AU  - Ćulafić, Milica
AU  - Roganović, Maša
AU  - Jovanović, Marija
AU  - Vezmar-Kovačević, Sandra
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4391
AB  - Hronična opstruktivna bolest pluća (HOBP) je oboljenje sa visokom prevalencom koje
karakteriše progresivna, ireverzibilna opstrukcija disajnih puteva često udružena sa
pojačanim inflamatornim odgovorom. Simptomi dispneje, kašlja i umora mogu negativno
uticati na kvalitet života obolelih. HOBP je često udružen sa drugim hroničnim bolestima što
doprinosi njegovom morbiditetu i mortalitetu. Cilj ovog istraživanja je procena terapije u
lečenju HOBP i pridruženih komorbiditeta. Sprovedena je opservaciona studija koja je
uključila pacijente koji su dolazili u javne apoteke da preuzmu lek na recept za lečenje HOBP.
Podaci o pacijentima su prikupljeni popunjavanjem upitnika. Deskriptivna analiza urađena je
u programu Microsoft ® Office Excel 2010. U istraživanje je uključeno 82 ispitanika, od kojih
su brojniji bili muškarci (56,1%). Prosečna starost ispitanika iznosila je 66,1±10,6, sa
prosečnim trajanjem bolesti 10,2±3,8 godina. Najveći broj (89%) primenjivao je
kombinovane inhalacione preparate (antiholinergik+β-agonista), antiholinergik 46,3%,
salbutamol 24,4%, teofilin/aminofilin 26,9%, inhalacioni kortikosteroid 11.0%, antibiotike
14,6% i oralne kortikosteroide 4,9%. Čak 97,6% pacijenata imao je pridruženu hroničnu
bolest - broj komorbiditeta po pacijentu 1-5. U 73,8% slučajeva je u pitanju hipertenzija,
21,3% imalo je astmu, i 12,2% dijabetes ili srčanu slabost. Primenom mMRC (modified
Medical Research Council) skale za procenu dispneje, vrednosti ≥2 imalo je 53,7% ispitanika
što ukazuje na slabo kontrolisanu bolest. Skoro četvrtina pacijenata bila je hospitalizovana
zbog egzacerbacije (23,2%), 53,7% vakcinisano protiv gripa, a samo 3,7% protiv
pneumokoka. Oko trećina ispitanika bili su pušači (35,4%). Uzimajući u obzir zastupljenost
komorbiditeta u ovoj populaciji i složenost terapije, savetovanje i praćenje od strane
farmaceuta moglo bi značajno doprineti sprečavanju potencijalnih terapijskih problema.
AB  - Chronic obstructive pulmonary disease (COPD) is a highly prevalent disease
characterized by progressive, irreversible airway obstruction often associated with
increased inflammatory response. Symptoms including dyspnea, cough and fatigue can
negatively affect patients’ quality of life. COPD is often associated with other chronic diseases
that contribute to its morbidity and mortality. The aim of this research was to evaluate the
therapy of COPD and comorbidities. An observational study included patients with a
prescription for COPD medications. Patients’ data were collected by completing
questionnaires in the community pharmacies. Descriptive analysis was performed in
Microsoft® Office Excel 2010. Among 82 participants most of them were men (56.1%).
Participants’ average age was 66.1±10.6 with an average disease duration of 10.2±3.8 years.
Most participants (89%) used combined inhalation preparations (anticholinergic+β-agonist),
anticholinergic 46.3%, salbutamol 24.4%, theophylline/aminophylline 26.9%, inhaled
corticosteroid 11.0%, antibiotics 14.6% and oral corticosteroids 4.9%. Additional chronic
disease was present in 97.6% of patients, with 1-5 comorbidities per patient. The majority of
patients also had hypertension 73.8%, 21.3% asthma and 12.2% diabetes or heart failure.
Using the mMRC (modified Medical Research Council) scale for the assessment of dyspnea,
53.7% had a score ≥2, indicating a poorly controlled disease. Almost a quarter of patients
were hospitalized for exacerbation (23.2%), 53.7% were vaccinated against influenza, only
3.7% against pneumococcus and about a third were smokers (35.4%). Given the prevalence
of comorbidities in this population and the complexity of therapy, counseling and monitoring
by pharmacists could make a significant contribution to preventing potential drug-related
problems.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Procena terapije i komorbiditeta kod pacijenata sa hroničnom opstruktivnom bolešću pluća
T1  - Assessment of therapy and comorbidities in patients with chronic obstructive pulmonary disease
VL  - 72
IS  - 4-suplement
SP  - S282
EP  - S283
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4391
ER  - 

@conference{
author = "Marković, Aleksandra and Kovačević, Milena and Ćulafić, Milica and Roganović, Maša and Jovanović, Marija and Vezmar-Kovačević, Sandra and Vučićević, Katarina and Miljković, Branislava",
year = "2022",
abstract = "Hronična opstruktivna bolest pluća (HOBP) je oboljenje sa visokom prevalencom koje
karakteriše progresivna, ireverzibilna opstrukcija disajnih puteva često udružena sa
pojačanim inflamatornim odgovorom. Simptomi dispneje, kašlja i umora mogu negativno
uticati na kvalitet života obolelih. HOBP je često udružen sa drugim hroničnim bolestima što
doprinosi njegovom morbiditetu i mortalitetu. Cilj ovog istraživanja je procena terapije u
lečenju HOBP i pridruženih komorbiditeta. Sprovedena je opservaciona studija koja je
uključila pacijente koji su dolazili u javne apoteke da preuzmu lek na recept za lečenje HOBP.
Podaci o pacijentima su prikupljeni popunjavanjem upitnika. Deskriptivna analiza urađena je
u programu Microsoft ® Office Excel 2010. U istraživanje je uključeno 82 ispitanika, od kojih
su brojniji bili muškarci (56,1%). Prosečna starost ispitanika iznosila je 66,1±10,6, sa
prosečnim trajanjem bolesti 10,2±3,8 godina. Najveći broj (89%) primenjivao je
kombinovane inhalacione preparate (antiholinergik+β-agonista), antiholinergik 46,3%,
salbutamol 24,4%, teofilin/aminofilin 26,9%, inhalacioni kortikosteroid 11.0%, antibiotike
14,6% i oralne kortikosteroide 4,9%. Čak 97,6% pacijenata imao je pridruženu hroničnu
bolest - broj komorbiditeta po pacijentu 1-5. U 73,8% slučajeva je u pitanju hipertenzija,
21,3% imalo je astmu, i 12,2% dijabetes ili srčanu slabost. Primenom mMRC (modified
Medical Research Council) skale za procenu dispneje, vrednosti ≥2 imalo je 53,7% ispitanika
što ukazuje na slabo kontrolisanu bolest. Skoro četvrtina pacijenata bila je hospitalizovana
zbog egzacerbacije (23,2%), 53,7% vakcinisano protiv gripa, a samo 3,7% protiv
pneumokoka. Oko trećina ispitanika bili su pušači (35,4%). Uzimajući u obzir zastupljenost
komorbiditeta u ovoj populaciji i složenost terapije, savetovanje i praćenje od strane
farmaceuta moglo bi značajno doprineti sprečavanju potencijalnih terapijskih problema., Chronic obstructive pulmonary disease (COPD) is a highly prevalent disease
characterized by progressive, irreversible airway obstruction often associated with
increased inflammatory response. Symptoms including dyspnea, cough and fatigue can
negatively affect patients’ quality of life. COPD is often associated with other chronic diseases
that contribute to its morbidity and mortality. The aim of this research was to evaluate the
therapy of COPD and comorbidities. An observational study included patients with a
prescription for COPD medications. Patients’ data were collected by completing
questionnaires in the community pharmacies. Descriptive analysis was performed in
Microsoft® Office Excel 2010. Among 82 participants most of them were men (56.1%).
Participants’ average age was 66.1±10.6 with an average disease duration of 10.2±3.8 years.
Most participants (89%) used combined inhalation preparations (anticholinergic+β-agonist),
anticholinergic 46.3%, salbutamol 24.4%, theophylline/aminophylline 26.9%, inhaled
corticosteroid 11.0%, antibiotics 14.6% and oral corticosteroids 4.9%. Additional chronic
disease was present in 97.6% of patients, with 1-5 comorbidities per patient. The majority of
patients also had hypertension 73.8%, 21.3% asthma and 12.2% diabetes or heart failure.
Using the mMRC (modified Medical Research Council) scale for the assessment of dyspnea,
53.7% had a score ≥2, indicating a poorly controlled disease. Almost a quarter of patients
were hospitalized for exacerbation (23.2%), 53.7% were vaccinated against influenza, only
3.7% against pneumococcus and about a third were smokers (35.4%). Given the prevalence
of comorbidities in this population and the complexity of therapy, counseling and monitoring
by pharmacists could make a significant contribution to preventing potential drug-related
problems.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Procena terapije i komorbiditeta kod pacijenata sa hroničnom opstruktivnom bolešću pluća, Assessment of therapy and comorbidities in patients with chronic obstructive pulmonary disease",
volume = "72",
number = "4-suplement",
pages = "S282-S283",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4391"
}

Marković, A., Kovačević, M., Ćulafić, M., Roganović, M., Jovanović, M., Vezmar-Kovačević, S., Vučićević, K.,& Miljković, B.. (2022). Procena terapije i komorbiditeta kod pacijenata sa hroničnom opstruktivnom bolešću pluća. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4-suplement), S282-S283.
https://hdl.handle.net/21.15107/rcub_farfar_4391

Marković A, Kovačević M, Ćulafić M, Roganović M, Jovanović M, Vezmar-Kovačević S, Vučićević K, Miljković B. Procena terapije i komorbiditeta kod pacijenata sa hroničnom opstruktivnom bolešću pluća. in Arhiv za farmaciju. 2022;72(4-suplement):S282-S283.
https://hdl.handle.net/21.15107/rcub_farfar_4391 .

Marković, Aleksandra, Kovačević, Milena, Ćulafić, Milica, Roganović, Maša, Jovanović, Marija, Vezmar-Kovačević, Sandra, Vučićević, Katarina, Miljković, Branislava, "Procena terapije i komorbiditeta kod pacijenata sa hroničnom opstruktivnom bolešću pluća" in Arhiv za farmaciju, 72, no. 4-suplement (2022):S282-S283,
https://hdl.handle.net/21.15107/rcub_farfar_4391 .

TY  - CONF
AU  - Lazarević, Katarina
AU  - Kovačević, Milena
AU  - Ćulafić, Milica
AU  - Jovanović, Marija
AU  - Roganović, Maša
AU  - Vezmar-Kovačević, Sandra
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4390
AB  - Astma predstavlja veliko globalno opterećenje jer se uprkos dostupnoj terapiji beleže
loši zdravstveni i socio-ekonomski ishodi. Cilj ovog rada je analiza primenjene terapije i
koterapije kod pacijenata obolelih od astme i identifikacija terapijskih problema. Sprovedena
opservaciona studija je uključila 57 odraslih pacijenata sa astmom, oba pola. Podaci su
prikupljani tokom 2016. godine u javnim apotekama, popunjavanjem upitnika. Deskriptivna
analiza je izvršena u programu Microsoft ® Office Excel 2010. Prosečna starost iznosila je
49,7±17,4 godina, 38,6% činili su muškarci. Kratkodelujuće beta-2 agoniste primenjivalo je
36,8% pacijenata, dugodelujuće beta-2 agoniste 8,8%, inhalacione kortikosteroide 28,1%,
dok je kombinovane preparate upotrebljavalo 73,7%. Više od 50% koristilo je inhalacione
antiholinergike, a primećena je upotreba teofilina/aminofilina kod 31,6%, što nije u
saglasnosti sa smernicama za terapiju astme usled slabe efikasnosti, odnosno lošeg
bezbednosnog profila. Takođe, ovaj rezultat može ukazati na to da pacijenti ne prihvataju
inhalacionu terapiju zbog zahtevnijeg načina primene ili zbog više cene lekova. Od
pridruženih komorbiditeta, najčešći su bili alergijski rinitis, gojaznost, hipertenzija i
gastroezofagealna refluksna bolest. Potencijalno neadekvatna koterapija uključivala je beta-
blokatore (21,1%), inhibitore angiotenzin-konvertujućeg enzima (28,1%), acetilsalicilnu
kiselinu/nesteroidne antiinflamatorne lekove (21,1% i 29,8%) čija primena može
precipitirati pogoršanje astme. Obeshrabrujuće je da su 26,3% pacijenata pušači, 35,1% ne
zna koji su okidači za njihovu bolest, a samo 1 pacijent koristi astma akcioni plan. Rezultati
ukazuju na veću zastupljenost terapije koja odgovara težim stadijumima astme, što može
ukazivati na lošiju kontrolu bolesti i lošije ishode. Uočava se potreba za uvođenjem usluga
farmaceutske zdravstvene zaštite i boljom edukacijom pacijenata o astmi.
AB  - Asthma represents a serious global burden because, despite available therapy, poor
health and socio-economic outcomes are reported. The aim of this paper is to analyse
treatment in patients with asthma and to identify drug-related problems. An observational
study included 57 adult asthma patients of both genders. Data were collected in community
pharmacies during 2016, by filling out questionnaires. Descriptive analysis was performed in
Microsoft® Office Excel 2010. Respondents’ average age was 49.7±17.4, 38.6% were men.
Patients used short-acting (36.8%) and long-acting beta-2 agonists (8.8%), inhaled
corticosteroids (28.1%) and combined preparations (73.7%). More than 50% of patients
used inhaled anticholinergics, while theophylline was used in 31.6%, which is in discordance
with the asthma guidelines, due to poor efficacy and safety profile. Also, this may indicate
that patients do not accept inhalation therapy because of demanding technique or higher
cost. Allergic rhinitis, obesity, hypertension, and gastroesophageal reflux disease were the
most common comorbidities. Potentially inadequate co-therapy included beta-blockers
(21.1%), angiotensin-converting enzyme inhibitors (28.1%), aspirin/nonsteroidal
antiinflamatory drugs (21.1% and 29.8%), which may worsen asthma. It is discouraging that
26.3% of patients were smokers, 35.1% did not know the triggers for asthma, and only 1
patient used the asthma action plan. The results show a higher prevalence of therapy
appropriate for severe asthma stages, which implies poor disease control and poor
outcomes. There is a need for the implementation of pharmaceutical care services and better
education of patients with asthma.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Pregled terapije i terapijskih problema kod pacijenata sa astmom u primarnoj zdravstvenoj zaštiti
T1  - Review of therapy and therapeutic problems in patients with asthma in primary health care
VL  - 72
IS  - 4-suplement
SP  - S280
EP  - S281
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4390
ER  - 

@conference{
author = "Lazarević, Katarina and Kovačević, Milena and Ćulafić, Milica and Jovanović, Marija and Roganović, Maša and Vezmar-Kovačević, Sandra and Vučićević, Katarina and Miljković, Branislava",
year = "2022",
abstract = "Astma predstavlja veliko globalno opterećenje jer se uprkos dostupnoj terapiji beleže
loši zdravstveni i socio-ekonomski ishodi. Cilj ovog rada je analiza primenjene terapije i
koterapije kod pacijenata obolelih od astme i identifikacija terapijskih problema. Sprovedena
opservaciona studija je uključila 57 odraslih pacijenata sa astmom, oba pola. Podaci su
prikupljani tokom 2016. godine u javnim apotekama, popunjavanjem upitnika. Deskriptivna
analiza je izvršena u programu Microsoft ® Office Excel 2010. Prosečna starost iznosila je
49,7±17,4 godina, 38,6% činili su muškarci. Kratkodelujuće beta-2 agoniste primenjivalo je
36,8% pacijenata, dugodelujuće beta-2 agoniste 8,8%, inhalacione kortikosteroide 28,1%,
dok je kombinovane preparate upotrebljavalo 73,7%. Više od 50% koristilo je inhalacione
antiholinergike, a primećena je upotreba teofilina/aminofilina kod 31,6%, što nije u
saglasnosti sa smernicama za terapiju astme usled slabe efikasnosti, odnosno lošeg
bezbednosnog profila. Takođe, ovaj rezultat može ukazati na to da pacijenti ne prihvataju
inhalacionu terapiju zbog zahtevnijeg načina primene ili zbog više cene lekova. Od
pridruženih komorbiditeta, najčešći su bili alergijski rinitis, gojaznost, hipertenzija i
gastroezofagealna refluksna bolest. Potencijalno neadekvatna koterapija uključivala je beta-
blokatore (21,1%), inhibitore angiotenzin-konvertujućeg enzima (28,1%), acetilsalicilnu
kiselinu/nesteroidne antiinflamatorne lekove (21,1% i 29,8%) čija primena može
precipitirati pogoršanje astme. Obeshrabrujuće je da su 26,3% pacijenata pušači, 35,1% ne
zna koji su okidači za njihovu bolest, a samo 1 pacijent koristi astma akcioni plan. Rezultati
ukazuju na veću zastupljenost terapije koja odgovara težim stadijumima astme, što može
ukazivati na lošiju kontrolu bolesti i lošije ishode. Uočava se potreba za uvođenjem usluga
farmaceutske zdravstvene zaštite i boljom edukacijom pacijenata o astmi., Asthma represents a serious global burden because, despite available therapy, poor
health and socio-economic outcomes are reported. The aim of this paper is to analyse
treatment in patients with asthma and to identify drug-related problems. An observational
study included 57 adult asthma patients of both genders. Data were collected in community
pharmacies during 2016, by filling out questionnaires. Descriptive analysis was performed in
Microsoft® Office Excel 2010. Respondents’ average age was 49.7±17.4, 38.6% were men.
Patients used short-acting (36.8%) and long-acting beta-2 agonists (8.8%), inhaled
corticosteroids (28.1%) and combined preparations (73.7%). More than 50% of patients
used inhaled anticholinergics, while theophylline was used in 31.6%, which is in discordance
with the asthma guidelines, due to poor efficacy and safety profile. Also, this may indicate
that patients do not accept inhalation therapy because of demanding technique or higher
cost. Allergic rhinitis, obesity, hypertension, and gastroesophageal reflux disease were the
most common comorbidities. Potentially inadequate co-therapy included beta-blockers
(21.1%), angiotensin-converting enzyme inhibitors (28.1%), aspirin/nonsteroidal
antiinflamatory drugs (21.1% and 29.8%), which may worsen asthma. It is discouraging that
26.3% of patients were smokers, 35.1% did not know the triggers for asthma, and only 1
patient used the asthma action plan. The results show a higher prevalence of therapy
appropriate for severe asthma stages, which implies poor disease control and poor
outcomes. There is a need for the implementation of pharmaceutical care services and better
education of patients with asthma.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Pregled terapije i terapijskih problema kod pacijenata sa astmom u primarnoj zdravstvenoj zaštiti, Review of therapy and therapeutic problems in patients with asthma in primary health care",
volume = "72",
number = "4-suplement",
pages = "S280-S281",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4390"
}

Lazarević, K., Kovačević, M., Ćulafić, M., Jovanović, M., Roganović, M., Vezmar-Kovačević, S., Vučićević, K.,& Miljković, B.. (2022). Pregled terapije i terapijskih problema kod pacijenata sa astmom u primarnoj zdravstvenoj zaštiti. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4-suplement), S280-S281.
https://hdl.handle.net/21.15107/rcub_farfar_4390

Lazarević K, Kovačević M, Ćulafić M, Jovanović M, Roganović M, Vezmar-Kovačević S, Vučićević K, Miljković B. Pregled terapije i terapijskih problema kod pacijenata sa astmom u primarnoj zdravstvenoj zaštiti. in Arhiv za farmaciju. 2022;72(4-suplement):S280-S281.
https://hdl.handle.net/21.15107/rcub_farfar_4390 .

Lazarević, Katarina, Kovačević, Milena, Ćulafić, Milica, Jovanović, Marija, Roganović, Maša, Vezmar-Kovačević, Sandra, Vučićević, Katarina, Miljković, Branislava, "Pregled terapije i terapijskih problema kod pacijenata sa astmom u primarnoj zdravstvenoj zaštiti" in Arhiv za farmaciju, 72, no. 4-suplement (2022):S280-S281,
https://hdl.handle.net/21.15107/rcub_farfar_4390 .

TY  - CONF
AU  - Lazarević, Katarina
AU  - Marković, Aleksandra
AU  - Vezmar-Kovačević, Sandra
AU  - Jovanović, Marija
AU  - Ćulafić, Milica
AU  - Kovačević, Milena
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4389
AB  - Benigna hiperplazija prostate (BHP) predstavlja nekancerozno uvećanje prostate
povezano sa simptomima donjeg urinarnog trakta i spada u najčešća oboljenja starijih
muškaraca. Kako su u ovom dobu uobičajeni komorbiditeti, pre svega kardiovaskularna
(KVS) oboljenja, može se očekivati veliki broj klinički značajnih interakcija lekova. Svrha ove
studije bila je analiza učestalosti i vrste potencijalnih interakcija u terapiji starijih pacijenata
sa BHP i KVS oboljenjem. Sprovedeno retrospektivno istraživanje uključilo je 93 muškaraca
starijih od 65 godina, obolelih od BHP i hipertenzije ili nekog KVS oboljenja. Podaci o
pacijentima su prikupljani iz medicinske dokumentacije. Potencijalne interakcije su
identifikovane i procenjivane korišćenjem Lexicomp® elektronske baze podataka.
Deskriptivna analiza je obavljena u programu Microsoft ® Office Excel 2010. Prosečna starost
ispitanika iznosila je 75,3±6,05. Broj lekova u terapiji bio je u rasponu od 2 do 13. Pet ili više
lekova primenjivalo je 72,04% pacijenata. Detektovano je ukupno 509 interakcija, od kojih
čak 467 spada u klinički značajne (C, D, X). Najveći broj identifikovanih interakcija pripada
klasi C (85,46%), dok je 4,91% iz klase D, a samo 1,38% iz klase X. U okviru klase X, koja
ukazuje da treba izbegavati istovremenu primenu kombinacije lekova, najčešće se javljala
interakcija između dva α-blokatora. Zabeleženo je 412 farmakodinamskih i 47
farmakokinetičkih interakcija. Dvojni mehanizam je detektovan kod 29 interakcija, a 21 se
odvijao nepoznatim mehanizmom. Rezultati studije upućuju da uključivanje farmaceuta u
praćenje pacijenata sa BHP može biti korisno, imajući u vidu značajan broj identifikovanih
klinički značajnih interakcija.
AB  - Benign prostatic hyperplasia (BPH) represents a non-cancerous prostate enlargement
associated with lower urinary tract symptoms and is one of the most common diseases in
older men. As comorbidities, primarily cardiovascular diseases (CVD) are common in this
age group, a great number of clinically significant drug interactions can be expected. The aim
of this research was to estimate the frequency and type of potential interactions in the
treatment of elderly with BPH and CVD. A retrospective study included 93 men aged over 65
with BPH and hypertension or CVD. Patients’ data were collected from medical records.
Potential interactions were identified and assessed using the Lexicomp ® database.
Descriptive analysis was performed in Microsoft® Office Excel 2010. Patients’ average age
was 75.3±6.05. The number of drugs in therapy ranged from 2 to 13. Five or more drugs
were used by 72.04% of the patients. A total of 509 interactions were detected, of which 467
are clinically significant (C, D, X). Most interactions belonged to category C (85.46%), while
4.91% belonged to class D, and only 1.38% to class X. Within class X, which indicates that
concomitant use of drugs should be avoided, the interaction between the two α-blockers was
most frequent. 412 pharmacodynamic and 47 pharmacokinetic interactions were identified.
The dual mechanism was detected in 29 interactions, while for 21 the mechanism was
unknown. The obtained results suggest the involvement of pharmacists in the monitoring of
patients with BPH may be useful, given the great proportion of identified clinically significant
interactions.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Praćenje interakcija lekova kod starijih pacijenata sa benignom hiperplazijom prostate i kardiovaskularnim oboljenjima
T1  - Monitoring of drug interactions in elderly patients with benign prostatic hyperplasia and cardiovascular diseases
VL  - 72
IS  - 4-suplement
SP  - S278
EP  - S279
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4389
ER  - 

@conference{
author = "Lazarević, Katarina and Marković, Aleksandra and Vezmar-Kovačević, Sandra and Jovanović, Marija and Ćulafić, Milica and Kovačević, Milena and Vučićević, Katarina and Miljković, Branislava",
year = "2022",
abstract = "Benigna hiperplazija prostate (BHP) predstavlja nekancerozno uvećanje prostate
povezano sa simptomima donjeg urinarnog trakta i spada u najčešća oboljenja starijih
muškaraca. Kako su u ovom dobu uobičajeni komorbiditeti, pre svega kardiovaskularna
(KVS) oboljenja, može se očekivati veliki broj klinički značajnih interakcija lekova. Svrha ove
studije bila je analiza učestalosti i vrste potencijalnih interakcija u terapiji starijih pacijenata
sa BHP i KVS oboljenjem. Sprovedeno retrospektivno istraživanje uključilo je 93 muškaraca
starijih od 65 godina, obolelih od BHP i hipertenzije ili nekog KVS oboljenja. Podaci o
pacijentima su prikupljani iz medicinske dokumentacije. Potencijalne interakcije su
identifikovane i procenjivane korišćenjem Lexicomp® elektronske baze podataka.
Deskriptivna analiza je obavljena u programu Microsoft ® Office Excel 2010. Prosečna starost
ispitanika iznosila je 75,3±6,05. Broj lekova u terapiji bio je u rasponu od 2 do 13. Pet ili više
lekova primenjivalo je 72,04% pacijenata. Detektovano je ukupno 509 interakcija, od kojih
čak 467 spada u klinički značajne (C, D, X). Najveći broj identifikovanih interakcija pripada
klasi C (85,46%), dok je 4,91% iz klase D, a samo 1,38% iz klase X. U okviru klase X, koja
ukazuje da treba izbegavati istovremenu primenu kombinacije lekova, najčešće se javljala
interakcija između dva α-blokatora. Zabeleženo je 412 farmakodinamskih i 47
farmakokinetičkih interakcija. Dvojni mehanizam je detektovan kod 29 interakcija, a 21 se
odvijao nepoznatim mehanizmom. Rezultati studije upućuju da uključivanje farmaceuta u
praćenje pacijenata sa BHP može biti korisno, imajući u vidu značajan broj identifikovanih
klinički značajnih interakcija., Benign prostatic hyperplasia (BPH) represents a non-cancerous prostate enlargement
associated with lower urinary tract symptoms and is one of the most common diseases in
older men. As comorbidities, primarily cardiovascular diseases (CVD) are common in this
age group, a great number of clinically significant drug interactions can be expected. The aim
of this research was to estimate the frequency and type of potential interactions in the
treatment of elderly with BPH and CVD. A retrospective study included 93 men aged over 65
with BPH and hypertension or CVD. Patients’ data were collected from medical records.
Potential interactions were identified and assessed using the Lexicomp ® database.
Descriptive analysis was performed in Microsoft® Office Excel 2010. Patients’ average age
was 75.3±6.05. The number of drugs in therapy ranged from 2 to 13. Five or more drugs
were used by 72.04% of the patients. A total of 509 interactions were detected, of which 467
are clinically significant (C, D, X). Most interactions belonged to category C (85.46%), while
4.91% belonged to class D, and only 1.38% to class X. Within class X, which indicates that
concomitant use of drugs should be avoided, the interaction between the two α-blockers was
most frequent. 412 pharmacodynamic and 47 pharmacokinetic interactions were identified.
The dual mechanism was detected in 29 interactions, while for 21 the mechanism was
unknown. The obtained results suggest the involvement of pharmacists in the monitoring of
patients with BPH may be useful, given the great proportion of identified clinically significant
interactions.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Praćenje interakcija lekova kod starijih pacijenata sa benignom hiperplazijom prostate i kardiovaskularnim oboljenjima, Monitoring of drug interactions in elderly patients with benign prostatic hyperplasia and cardiovascular diseases",
volume = "72",
number = "4-suplement",
pages = "S278-S279",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4389"
}

Lazarević, K., Marković, A., Vezmar-Kovačević, S., Jovanović, M., Ćulafić, M., Kovačević, M., Vučićević, K.,& Miljković, B.. (2022). Praćenje interakcija lekova kod starijih pacijenata sa benignom hiperplazijom prostate i kardiovaskularnim oboljenjima. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4-suplement), S278-S279.
https://hdl.handle.net/21.15107/rcub_farfar_4389

Lazarević K, Marković A, Vezmar-Kovačević S, Jovanović M, Ćulafić M, Kovačević M, Vučićević K, Miljković B. Praćenje interakcija lekova kod starijih pacijenata sa benignom hiperplazijom prostate i kardiovaskularnim oboljenjima. in Arhiv za farmaciju. 2022;72(4-suplement):S278-S279.
https://hdl.handle.net/21.15107/rcub_farfar_4389 .

Lazarević, Katarina, Marković, Aleksandra, Vezmar-Kovačević, Sandra, Jovanović, Marija, Ćulafić, Milica, Kovačević, Milena, Vučićević, Katarina, Miljković, Branislava, "Praćenje interakcija lekova kod starijih pacijenata sa benignom hiperplazijom prostate i kardiovaskularnim oboljenjima" in Arhiv za farmaciju, 72, no. 4-suplement (2022):S278-S279,
https://hdl.handle.net/21.15107/rcub_farfar_4389 .

TY  - CONF
AU  - Jovanović, Marija
AU  - Roganović, Maša
AU  - Kovačević, Milena
AU  - Ćulafić, Milica
AU  - Vučićević, Katarina
AU  - Vezmar-Kovačević, Sandra
AU  - Milenković, Branislava
AU  - Miljković, Branislava
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4388
AB  - Lečenje astme i hronične opstruktivne bolesti pluća (HOBP) zahteva optimalnu
upotrebu inhalatora. Farmaceuti imaju značajnu ulogu u edukaciji pacijenata o pravilnoj
upotrebi inhalatora, uključujuć i inhalatore za suvi prašak (eng. Dry Powder Inhalers, DPI). Cilj
studije je bio da se procene i uporede veštine demonstracije farmaceuta za DPI pre i posle
edukacije. U studiju su uključeni samo farmaceuti bez prethodne obuke za pravilnu upotrebu
inhalatora. Skor farmaceuta je procenjen na početku i nakon obuke za pravilnu upotrebu 5
tipova DPI. Učesnici su dobijali 1 poen za svaki od četiri pravilno izvedenih koraka.
Statistička analiza je izvršena korišćenjem SPSS programa (verzija 25). Wilcoxon test je
korišćen za poređenje rezultata pre i posle edukacije. Prosečan skor nakon obuke bio je
3,8±0,57 za sve tipove DPI. Uočena je statistički značajna razlika (p<0,05) u postignutim
skorovama pre i posle obuke farmaceuta uzimajući u obzir 594 poređenja. U 575 slučajeva
skor je bio viši nakon obuke, u samo 2 slučaja skor je bio niži, dok je u 17 slučajeva bio
izjednačen. Ukupna stopa greške za prvi korak (priprema uređaja) bila je 2,86%, za drugi
korak (izdisaj) 4,71%, za treć i korak (udisaj) 6,73% i za poslednji korak (zadržavanje daha)
5,56%. Rezultati ukazuju da je obuka unapredila veštine farmaceuta u vezi sa tehnikom
primene DPI. To može doprineti boljoj kontroli astme i HOBP, nakon edukacije pacijenata.
Ovo je posebno važno imajući u vidu da su farmaceuti najpristupačniji zdravstveni radnici.
AB  - Treatment of asthma and chronic obstructive pulmonary disease (COPD) requires
optimal use of inhalers. Pharmacists have a significant role in educating patients on the
correct use of inhalers, including dry powder inhalers (DPI). The aim of the study was to
assess and compare pharmacists’ DPI technique demonstration skills before and after the
education. The study included only pharmacists without previous training for correct use of
inhalers. Pharmacists’ score was assessed at baseline and after the training of the correct use
of 5 types of DPI. The participants were given a 1-point score for each of four steps
performed correctly. Statistical analysis was performed using the SPSS program (version
25). Wilcoxon test was used for score comparison before and after education. The mean
score after training was 3.8±0.57 for all types of DPI. There was a statistically significant
difference (p<0.05) in achieved scores before and after pharmacists' training taking into
account 594 comparisons. In 575 cases the score was higher after training, in only 2 cases
the score was lower, while in 17 cases it was even. The total error rate for first step (device
preparation) was 2.86%, for second step (expiration) it was 4.71%, for third step
(inhalation) it was 6.73% and for last step (holding breath) it was 5.56%. The results imply
that training improved pharmacist skills regarding the DPI technique. It may contribute to
better control of asthma and COPD, after education of patients. This is especially important
considering that pharmacist are the most accessible health care professionals.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Procena tehnike inhalacije farmaceuta u primarnoj zdravstvenoj zaštiti ‐ fokus na inhalatore za suvi prašak
T1  - Evaluation of inhalation technique of community pharmacists - focus on dry powder inhalers
VL  - 72
IS  - 4-suplement
SP  - S274
EP  - S275
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4388
ER  - 

@conference{
author = "Jovanović, Marija and Roganović, Maša and Kovačević, Milena and Ćulafić, Milica and Vučićević, Katarina and Vezmar-Kovačević, Sandra and Milenković, Branislava and Miljković, Branislava",
year = "2022",
abstract = "Lečenje astme i hronične opstruktivne bolesti pluća (HOBP) zahteva optimalnu
upotrebu inhalatora. Farmaceuti imaju značajnu ulogu u edukaciji pacijenata o pravilnoj
upotrebi inhalatora, uključujuć i inhalatore za suvi prašak (eng. Dry Powder Inhalers, DPI). Cilj
studije je bio da se procene i uporede veštine demonstracije farmaceuta za DPI pre i posle
edukacije. U studiju su uključeni samo farmaceuti bez prethodne obuke za pravilnu upotrebu
inhalatora. Skor farmaceuta je procenjen na početku i nakon obuke za pravilnu upotrebu 5
tipova DPI. Učesnici su dobijali 1 poen za svaki od četiri pravilno izvedenih koraka.
Statistička analiza je izvršena korišćenjem SPSS programa (verzija 25). Wilcoxon test je
korišćen za poređenje rezultata pre i posle edukacije. Prosečan skor nakon obuke bio je
3,8±0,57 za sve tipove DPI. Uočena je statistički značajna razlika (p<0,05) u postignutim
skorovama pre i posle obuke farmaceuta uzimajući u obzir 594 poređenja. U 575 slučajeva
skor je bio viši nakon obuke, u samo 2 slučaja skor je bio niži, dok je u 17 slučajeva bio
izjednačen. Ukupna stopa greške za prvi korak (priprema uređaja) bila je 2,86%, za drugi
korak (izdisaj) 4,71%, za treć i korak (udisaj) 6,73% i za poslednji korak (zadržavanje daha)
5,56%. Rezultati ukazuju da je obuka unapredila veštine farmaceuta u vezi sa tehnikom
primene DPI. To može doprineti boljoj kontroli astme i HOBP, nakon edukacije pacijenata.
Ovo je posebno važno imajući u vidu da su farmaceuti najpristupačniji zdravstveni radnici., Treatment of asthma and chronic obstructive pulmonary disease (COPD) requires
optimal use of inhalers. Pharmacists have a significant role in educating patients on the
correct use of inhalers, including dry powder inhalers (DPI). The aim of the study was to
assess and compare pharmacists’ DPI technique demonstration skills before and after the
education. The study included only pharmacists without previous training for correct use of
inhalers. Pharmacists’ score was assessed at baseline and after the training of the correct use
of 5 types of DPI. The participants were given a 1-point score for each of four steps
performed correctly. Statistical analysis was performed using the SPSS program (version
25). Wilcoxon test was used for score comparison before and after education. The mean
score after training was 3.8±0.57 for all types of DPI. There was a statistically significant
difference (p<0.05) in achieved scores before and after pharmacists' training taking into
account 594 comparisons. In 575 cases the score was higher after training, in only 2 cases
the score was lower, while in 17 cases it was even. The total error rate for first step (device
preparation) was 2.86%, for second step (expiration) it was 4.71%, for third step
(inhalation) it was 6.73% and for last step (holding breath) it was 5.56%. The results imply
that training improved pharmacist skills regarding the DPI technique. It may contribute to
better control of asthma and COPD, after education of patients. This is especially important
considering that pharmacist are the most accessible health care professionals.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Procena tehnike inhalacije farmaceuta u primarnoj zdravstvenoj zaštiti ‐ fokus na inhalatore za suvi prašak, Evaluation of inhalation technique of community pharmacists - focus on dry powder inhalers",
volume = "72",
number = "4-suplement",
pages = "S274-S275",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4388"
}

Jovanović, M., Roganović, M., Kovačević, M., Ćulafić, M., Vučićević, K., Vezmar-Kovačević, S., Milenković, B.,& Miljković, B.. (2022). Procena tehnike inhalacije farmaceuta u primarnoj zdravstvenoj zaštiti ‐ fokus na inhalatore za suvi prašak. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4-suplement), S274-S275.
https://hdl.handle.net/21.15107/rcub_farfar_4388

Jovanović M, Roganović M, Kovačević M, Ćulafić M, Vučićević K, Vezmar-Kovačević S, Milenković B, Miljković B. Procena tehnike inhalacije farmaceuta u primarnoj zdravstvenoj zaštiti ‐ fokus na inhalatore za suvi prašak. in Arhiv za farmaciju. 2022;72(4-suplement):S274-S275.
https://hdl.handle.net/21.15107/rcub_farfar_4388 .

Jovanović, Marija, Roganović, Maša, Kovačević, Milena, Ćulafić, Milica, Vučićević, Katarina, Vezmar-Kovačević, Sandra, Milenković, Branislava, Miljković, Branislava, "Procena tehnike inhalacije farmaceuta u primarnoj zdravstvenoj zaštiti ‐ fokus na inhalatore za suvi prašak" in Arhiv za farmaciju, 72, no. 4-suplement (2022):S274-S275,
https://hdl.handle.net/21.15107/rcub_farfar_4388 .

TY  - CONF
AU  - Homšek, Ana
AU  - Jovanović, Marija
AU  - Roganović, Maša
AU  - Kovačević, Milena
AU  - Ćulafić, Milica
AU  - Vezmar-Kovačević, Sandra
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4387
AB  - Kako glavobolje predstavljaju jedno od najčešćih onesposobljavajućih stanja u svetu, 1
a mogu se lečiti lekovima koji se izdaju bez recepta, uloga farmaceuta u zbrinjavanju ovih
pacijenata prepoznata je kao veoma značajna. Cilj istraživanja bio je da se ispitaju percepcije
farmaceuta u primarnoj zdravstvenoj zaštiti o pružanju usluge pacijentima, kao i o
sprovedenoj edukaciji specijalizovanoj ka glavoboljama. Podaci su prikupljani putem ankete,
prilagođene prema prethodnom radu2 i obrađeni u programima SPSS i Microsoft Excel.
Popunjavanju ankete pristupilo je 43 farmaceuta iz primarne zdravstvene zaštite (90,7%
žene, raspon godina 27-64). Provera pouzdanosti ankete potvrđena je upotrebom Cronbach-
ovog testa (αB = 0,727; αC = 0,880). Najveći broj anketiranih farmaceuta smatra da pažljivo
sluša pacijente sa glavoboljom (65% uvek, 27,9% često), interakcije uvek proverava čak
44,7%, dok o pravilnoj primeni leka njih 86,04% uvek posavetuje pacijenta. Međutim,
34,88% prijavljuje da nikada ne kontaktira lekare ukoliko je lek skup, ne refundira se ili
izaziva neželjenu reakciju koja ograničava primenu, a 32,55% samo ponekad to učini. Većina
farmaceuta smatra da je edukacija korisna za bolje razumevanje pacijenata i savetovanje o
glavoboljama (97,67-100%), dok nešto manji procenat (93,02%) smatra da je edukacija
korisna da lakše prepoznaju pacijenta sa migrenom i upute ga lekaru. Percepcija većine
farmaceuta je da savetuje pacijente o terapiji glavobolje i bez prethodne edukacije, ali da bi
uz edukaciju usluga koju pružaju bila kompletnija. Rezultati studije upućuju da buduće
edukacije treba fokusirati na unapređenje komunikacije sa lekarima.
AB  - Since headaches represent one of the most common disabling conditions in the world1
and can be treated with over-the-counter drugs, the role of pharmacists in caring for these
patients has been recognized as very important. The research aim was to review primary
health care pharmacists’ perception regarding patient service they provide and the
conducted education devoted to headaches. Data were collected through a survey adapted
from the published article 2 and analysed in SPSS and Microsoft Excel. The survey was
completed by 43 primary health care pharmacists (90.7% women, age 27-64). The survey
reliability was verified using the Cronbach’s test (αB = 0.727; αC = 0.880). Most of the
surveyed pharmacists believe that they listen carefully to patients with headaches (65%
always, 27.9% often), 44.7% always check interactions, while 86.04% always advise the
patient on proper drug administration. However, 34.88% report that they never contact
doctors if the drug is expensive, not reimbursable or causes an adverse reaction that limits
its use, and 32.55% only sometimes do so. Most pharmacists believe education was useful to
better understand patients and counsel them about headaches (97.67-100%), while a
slightly smaller percentage (93.02%) thinks it helped them learn to identify a migraine
patient and refer him to a doctor. The perception of most pharmacists is that they advise
patients on headache treatment even without prior education, but after it, the service would
be more complete. The study results indicate that future education should focus on
improving communication with doctors.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Percepcija farmaceuta o pružanju usluge pacijentima sa glavoboljom u primarnoj zdravstvenoj zaštiti
T1  - Pharmacists’ perception about providing services to patients with headaches in primary care
VL  - 72
IS  - 4 suplement
SP  - S264
EP  - S265
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4387
ER  - 

@conference{
author = "Homšek, Ana and Jovanović, Marija and Roganović, Maša and Kovačević, Milena and Ćulafić, Milica and Vezmar-Kovačević, Sandra and Vučićević, Katarina and Miljković, Branislava",
year = "2022",
abstract = "Kako glavobolje predstavljaju jedno od najčešćih onesposobljavajućih stanja u svetu, 1
a mogu se lečiti lekovima koji se izdaju bez recepta, uloga farmaceuta u zbrinjavanju ovih
pacijenata prepoznata je kao veoma značajna. Cilj istraživanja bio je da se ispitaju percepcije
farmaceuta u primarnoj zdravstvenoj zaštiti o pružanju usluge pacijentima, kao i o
sprovedenoj edukaciji specijalizovanoj ka glavoboljama. Podaci su prikupljani putem ankete,
prilagođene prema prethodnom radu2 i obrađeni u programima SPSS i Microsoft Excel.
Popunjavanju ankete pristupilo je 43 farmaceuta iz primarne zdravstvene zaštite (90,7%
žene, raspon godina 27-64). Provera pouzdanosti ankete potvrđena je upotrebom Cronbach-
ovog testa (αB = 0,727; αC = 0,880). Najveći broj anketiranih farmaceuta smatra da pažljivo
sluša pacijente sa glavoboljom (65% uvek, 27,9% često), interakcije uvek proverava čak
44,7%, dok o pravilnoj primeni leka njih 86,04% uvek posavetuje pacijenta. Međutim,
34,88% prijavljuje da nikada ne kontaktira lekare ukoliko je lek skup, ne refundira se ili
izaziva neželjenu reakciju koja ograničava primenu, a 32,55% samo ponekad to učini. Većina
farmaceuta smatra da je edukacija korisna za bolje razumevanje pacijenata i savetovanje o
glavoboljama (97,67-100%), dok nešto manji procenat (93,02%) smatra da je edukacija
korisna da lakše prepoznaju pacijenta sa migrenom i upute ga lekaru. Percepcija većine
farmaceuta je da savetuje pacijente o terapiji glavobolje i bez prethodne edukacije, ali da bi
uz edukaciju usluga koju pružaju bila kompletnija. Rezultati studije upućuju da buduće
edukacije treba fokusirati na unapređenje komunikacije sa lekarima., Since headaches represent one of the most common disabling conditions in the world1
and can be treated with over-the-counter drugs, the role of pharmacists in caring for these
patients has been recognized as very important. The research aim was to review primary
health care pharmacists’ perception regarding patient service they provide and the
conducted education devoted to headaches. Data were collected through a survey adapted
from the published article 2 and analysed in SPSS and Microsoft Excel. The survey was
completed by 43 primary health care pharmacists (90.7% women, age 27-64). The survey
reliability was verified using the Cronbach’s test (αB = 0.727; αC = 0.880). Most of the
surveyed pharmacists believe that they listen carefully to patients with headaches (65%
always, 27.9% often), 44.7% always check interactions, while 86.04% always advise the
patient on proper drug administration. However, 34.88% report that they never contact
doctors if the drug is expensive, not reimbursable or causes an adverse reaction that limits
its use, and 32.55% only sometimes do so. Most pharmacists believe education was useful to
better understand patients and counsel them about headaches (97.67-100%), while a
slightly smaller percentage (93.02%) thinks it helped them learn to identify a migraine
patient and refer him to a doctor. The perception of most pharmacists is that they advise
patients on headache treatment even without prior education, but after it, the service would
be more complete. The study results indicate that future education should focus on
improving communication with doctors.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Percepcija farmaceuta o pružanju usluge pacijentima sa glavoboljom u primarnoj zdravstvenoj zaštiti, Pharmacists’ perception about providing services to patients with headaches in primary care",
volume = "72",
number = "4 suplement",
pages = "S264-S265",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4387"
}

Homšek, A., Jovanović, M., Roganović, M., Kovačević, M., Ćulafić, M., Vezmar-Kovačević, S., Vučićević, K.,& Miljković, B.. (2022). Percepcija farmaceuta o pružanju usluge pacijentima sa glavoboljom u primarnoj zdravstvenoj zaštiti. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S264-S265.
https://hdl.handle.net/21.15107/rcub_farfar_4387

Homšek A, Jovanović M, Roganović M, Kovačević M, Ćulafić M, Vezmar-Kovačević S, Vučićević K, Miljković B. Percepcija farmaceuta o pružanju usluge pacijentima sa glavoboljom u primarnoj zdravstvenoj zaštiti. in Arhiv za farmaciju. 2022;72(4 suplement):S264-S265.
https://hdl.handle.net/21.15107/rcub_farfar_4387 .

Homšek, Ana, Jovanović, Marija, Roganović, Maša, Kovačević, Milena, Ćulafić, Milica, Vezmar-Kovačević, Sandra, Vučićević, Katarina, Miljković, Branislava, "Percepcija farmaceuta o pružanju usluge pacijentima sa glavoboljom u primarnoj zdravstvenoj zaštiti" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S264-S265,
https://hdl.handle.net/21.15107/rcub_farfar_4387 .

TY  - CONF
AU  - Kovačević, Milena
AU  - Ćulafić, Milica
AU  - Roganović, Maša
AU  - Jovanović, Marija
AU  - Vučićević, Katarina
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4396
AB  - Uverenja pacijenata mogu značajno uticati na stepen adherence i ishode terapije
hroničnih oboljenja. Cilj istraživanja bila je procena negativnih stavova (zabrinutosti)
odraslih pacijenata prema primeni terapije u lečenju astme i hronične opstruktivne bolesti
pluća (HOBP). Upitnik je obuhvatio demografske, podatke o terapiji, podatke o kontroli
bolesti (modified Medical Research Council–mMRC u HOBP, i Asthma Control Test–ACT u
astmi), i stavovima u pogledu zabrinutosti (Beliefs about Medicines Questionnaire-BMQ).
Korišćena je petostepena Likertova skala (1-uopšte se ne slažem, do 5–u potpunosti se
slažem). Analiza je izvršena primenom SPSS softvera (ver. 27). Istraživanjem je obuhvaćeno
145 pacijenata, 80 sa HOBP (55,2%) i 65 sa astmom (44,8%). Adekvatna kontrola bolesti
zabeležena je kod 42% (45% mMRC<2, 38,5% ACT≥20). Prosečna vrednost skora
zabrinutosti iznosila je 14,7±4,2 (opseg 6-25). Vrednost se nije statistički značajno
razlikovala između pacijenata sa astmom i HOBP, niti u zavisnosti od dužine trajanja bolesti.
Zabrinutost zbog primene lekova izrazilo je 55,9% pacijenata, dugoročnih posledica 44,1%,
razvoja zavisnosti 32,4%, nepoznavanja lekova 29,7% i uticaja na svakodnevni život 24,1%.
Literaturni podaci ukazuju na jaku povezanost negativnih stavova prema lekovima sa nižim
stepenom adherence, što nije bila tema našeg istraživanja, ali se može pretpostaviti da ti
rezultati doprinose lošoj kontroli bolesti u ispitivanoj grupi (<50%). Savetovanje pacijenata
u javnim apotekama o značaju redovne primene i odnosu korist/rizik od primene lekova u
lečenju astme i HOBP može biti značajna intervencija ka unapređenju stavova i ishoda
terapije.
AB  - Patients’ beliefs can significantly impact the adherence and outcomes of chronic
disease therapy. The aim of the study was to assess the negative attitudes (concerns) of adult
patients towards the use of medications for asthma and chronic obstructive pulmonary
disease (COPD). The questionnaire included demographics, data on therapy, disease control
(modified Medical Research Council-mMRC for COPD, and Asthma Control Test-ACT), and
concerns (Beliefs about Medicines Questionnaire-BMQ). A five-point Likert scale was used
(1-strongly disagree, to 5-strongly agree). Analysis was performed using SPSS software (ver.
27). The study included 145 patients, 80 COPD (55.2%) and 65 asthma (44.8%). Adequate
disease control was observed in 42% (45% mMRC <2, 38.5% ACT≥20). The mean concern
score was 14.7±4.2 (range 6–25). The score did not differ significantly between the patients
with asthma and COPD, nor depending on the disease duration. Concerns about the regular
use of medications were expressed by 55.9%, long-term consequences 44.1%, development
of addiction 32.4%, lack of knowledge 29.7% and the impact on everyday life 24.1%.
Literature data indicate a strong correlation between negative attitudes towards
medications with a lower level of adherence. It can be assumed that these results contribute
to poor disease control observed in our study (<50%). Patients’ counseling on the
importance of regular use and the benefit/risk ratio of asthma and COPD medications can be
a meaningful intervention in improving attitudes and therapy outcomes.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Zabrinutost u vezi sa primenom lekova kod pacijenata sa hroničnim respiratornim oboljenjima
T1  - Concerns about medications in patients with chronic respiratory disease
VL  - 72
IS  - 4 Suplement
SP  - S256
EP  - S257
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4396
ER  - 

@conference{
author = "Kovačević, Milena and Ćulafić, Milica and Roganović, Maša and Jovanović, Marija and Vučićević, Katarina and Vezmar-Kovačević, Sandra and Miljković, Branislava",
year = "2022",
abstract = "Uverenja pacijenata mogu značajno uticati na stepen adherence i ishode terapije
hroničnih oboljenja. Cilj istraživanja bila je procena negativnih stavova (zabrinutosti)
odraslih pacijenata prema primeni terapije u lečenju astme i hronične opstruktivne bolesti
pluća (HOBP). Upitnik je obuhvatio demografske, podatke o terapiji, podatke o kontroli
bolesti (modified Medical Research Council–mMRC u HOBP, i Asthma Control Test–ACT u
astmi), i stavovima u pogledu zabrinutosti (Beliefs about Medicines Questionnaire-BMQ).
Korišćena je petostepena Likertova skala (1-uopšte se ne slažem, do 5–u potpunosti se
slažem). Analiza je izvršena primenom SPSS softvera (ver. 27). Istraživanjem je obuhvaćeno
145 pacijenata, 80 sa HOBP (55,2%) i 65 sa astmom (44,8%). Adekvatna kontrola bolesti
zabeležena je kod 42% (45% mMRC<2, 38,5% ACT≥20). Prosečna vrednost skora
zabrinutosti iznosila je 14,7±4,2 (opseg 6-25). Vrednost se nije statistički značajno
razlikovala između pacijenata sa astmom i HOBP, niti u zavisnosti od dužine trajanja bolesti.
Zabrinutost zbog primene lekova izrazilo je 55,9% pacijenata, dugoročnih posledica 44,1%,
razvoja zavisnosti 32,4%, nepoznavanja lekova 29,7% i uticaja na svakodnevni život 24,1%.
Literaturni podaci ukazuju na jaku povezanost negativnih stavova prema lekovima sa nižim
stepenom adherence, što nije bila tema našeg istraživanja, ali se može pretpostaviti da ti
rezultati doprinose lošoj kontroli bolesti u ispitivanoj grupi (<50%). Savetovanje pacijenata
u javnim apotekama o značaju redovne primene i odnosu korist/rizik od primene lekova u
lečenju astme i HOBP može biti značajna intervencija ka unapređenju stavova i ishoda
terapije., Patients’ beliefs can significantly impact the adherence and outcomes of chronic
disease therapy. The aim of the study was to assess the negative attitudes (concerns) of adult
patients towards the use of medications for asthma and chronic obstructive pulmonary
disease (COPD). The questionnaire included demographics, data on therapy, disease control
(modified Medical Research Council-mMRC for COPD, and Asthma Control Test-ACT), and
concerns (Beliefs about Medicines Questionnaire-BMQ). A five-point Likert scale was used
(1-strongly disagree, to 5-strongly agree). Analysis was performed using SPSS software (ver.
27). The study included 145 patients, 80 COPD (55.2%) and 65 asthma (44.8%). Adequate
disease control was observed in 42% (45% mMRC <2, 38.5% ACT≥20). The mean concern
score was 14.7±4.2 (range 6–25). The score did not differ significantly between the patients
with asthma and COPD, nor depending on the disease duration. Concerns about the regular
use of medications were expressed by 55.9%, long-term consequences 44.1%, development
of addiction 32.4%, lack of knowledge 29.7% and the impact on everyday life 24.1%.
Literature data indicate a strong correlation between negative attitudes towards
medications with a lower level of adherence. It can be assumed that these results contribute
to poor disease control observed in our study (<50%). Patients’ counseling on the
importance of regular use and the benefit/risk ratio of asthma and COPD medications can be
a meaningful intervention in improving attitudes and therapy outcomes.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Zabrinutost u vezi sa primenom lekova kod pacijenata sa hroničnim respiratornim oboljenjima, Concerns about medications in patients with chronic respiratory disease",
volume = "72",
number = "4 Suplement",
pages = "S256-S257",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4396"
}

Kovačević, M., Ćulafić, M., Roganović, M., Jovanović, M., Vučićević, K., Vezmar-Kovačević, S.,& Miljković, B.. (2022). Zabrinutost u vezi sa primenom lekova kod pacijenata sa hroničnim respiratornim oboljenjima. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 Suplement), S256-S257.
https://hdl.handle.net/21.15107/rcub_farfar_4396

Kovačević M, Ćulafić M, Roganović M, Jovanović M, Vučićević K, Vezmar-Kovačević S, Miljković B. Zabrinutost u vezi sa primenom lekova kod pacijenata sa hroničnim respiratornim oboljenjima. in Arhiv za farmaciju. 2022;72(4 Suplement):S256-S257.
https://hdl.handle.net/21.15107/rcub_farfar_4396 .

Kovačević, Milena, Ćulafić, Milica, Roganović, Maša, Jovanović, Marija, Vučićević, Katarina, Vezmar-Kovačević, Sandra, Miljković, Branislava, "Zabrinutost u vezi sa primenom lekova kod pacijenata sa hroničnim respiratornim oboljenjima" in Arhiv za farmaciju, 72, no. 4 Suplement (2022):S256-S257,
https://hdl.handle.net/21.15107/rcub_farfar_4396 .

TY  - CONF
AU  - Kovačević, Milena
AU  - Jovanović, Marija
AU  - Ćulafić, Milica
AU  - Roganović, Maša
AU  - Vučićević, Katarina
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4386
AB  - Primena benzodiazepina kod starijih pacijenata povezana je sa brojnim neželjenim
ishodima, poput povećanog rizika od pada, fraktura, troškova u zdravstvenom sistemu, pa
čak i smrtnih ishoda. Cilj rada bio je određivanje učestalosti primene benzodiazepina kod
pacijenata starosti ≥65 godina, i procena povezanosti njihove primene sa karakteristikama
pacijenata. Podaci su prikupljeni prospektivno u javnim apotekama primenom upitnika koji
su obuhvatili demografske, kliničke i karakteristike terapije pacijenta. Obrada rezultata
izvršena je primenom softvera SPSS (ver. 25). U istraživanju je učestvovalo 287 pacijenata,
prosečne starosti 72,2±5,8 godina (ukupan opseg 65-91). Prosečan broj lekova po pacijentu
iznosio je 7,6±2,2 (4-18), dok je prosečan broj indikacija iznosio 4,5±1,7 (1-11). Ukupna
zastupljenost benzodiazepina iznosila je 28,9%, od čega su dugodelujući bili primenjivani
kod 24.0%, a kratkodelujući kod 5,2% pacijenata. Najčešće primenjivan lek iz ove grupe bio
je bromazepam (17,1%), potom diazepam (7.0%), lorazepam (3,8%) i alprazolam (1,4%). U
grupi pacijenata starosti 65-69 godina prevalenca primene benzodiazepina iznosila je 29,3%,
70-74 godina 33,7%, 75-80 godina 23,3% i kod starijih od 80 godina 24.0%. Primena
benzodiazepina bila je statistički značajno češća kod pacijenata sa dijagnozom anksioznosti,
drugog mentalnog oboljenja, ali i primenom bisfosfonata, analgetika ili biljnog leka ekstrakta
lista Ginko biloba (p<0,05). Određena je visoka učestalost primene benzodiazepina kod
starijih pacijenata. Farmaceuti u javnim apotekama mogu imati značajnu ulogu u proceni i
minimizaciji rizika od neželjenog događaja, koji uključuju savetovanje pacijenata o prevenciji
padova, ali i mogućnostima postepene obustave ovih lekova kada ne postoji ubedljiva
indikacija za njihovu dugotrajnu primenu.
AB  - The use of benzodiazepines in elderly patients is associated with the numerous adverse
outcomes, such as an increased risk of falls, fractures, health care costs, and even mortality.
The aim was to investigate the frequency of benzodiazepine use in patients aged ≥65 years,
and to explore the association of their use with patient characteristics. Demographic, clinical,
and therapy characteristics were collected prospectively in the community pharmacies. Data
analysis was performed using SPSS software (ver. 25). The study included 287 patients, with
a mean age of 72.2±5.8 years (total range 65-91), the average number of drugs 7.6±2.2 (4-
18), and the average number of indications 4.5±1.7 (1-11). The total prevalence of
benzodiazepine use was 28.9%, long-acting 24.0% and short-acting 5.2%. The most
commonly used was bromazepam (17.1%), followed by diazepam (7.0%), lorazepam (3.8%)
and alprazolam (1.4%). In the patients aged 65-69 years, the prevalence of benzodiazepine
use was 29.3%, 70-74 years 33.7%, 75-80 years 23.3% and in ≥80 years 24.0%. The use of
benzodiazepines was statistically significantly more common in patients diagnosed with
anxiety, other mental illness, but also with the comedication with bisphosphonates,
analgesics or herbal medicine Ginkgo biloba leaf extract (p<0.05). A high frequency of
benzodiazepine use was determined in elderly patients. Community pharmacists can play a
significant role in assessing and minimizing the risk of adverse events. Interventions may
include counseling on the prevention of falls, but also the possibility of drug discontinuation
when there is no convincing indication for their long-term use.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Učestalost primene benzodiazepina kod starijih pacijenata u primarnoj zdravstvenoj zaštiti
T1  - Frequency of benzodiazepine use in elderly primary care patients
VL  - 72
IS  - 4 suplement
SP  - S258
EP  - S259
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4386
ER  - 

@conference{
author = "Kovačević, Milena and Jovanović, Marija and Ćulafić, Milica and Roganović, Maša and Vučićević, Katarina and Vezmar-Kovačević, Sandra and Miljković, Branislava",
year = "2022",
abstract = "Primena benzodiazepina kod starijih pacijenata povezana je sa brojnim neželjenim
ishodima, poput povećanog rizika od pada, fraktura, troškova u zdravstvenom sistemu, pa
čak i smrtnih ishoda. Cilj rada bio je određivanje učestalosti primene benzodiazepina kod
pacijenata starosti ≥65 godina, i procena povezanosti njihove primene sa karakteristikama
pacijenata. Podaci su prikupljeni prospektivno u javnim apotekama primenom upitnika koji
su obuhvatili demografske, kliničke i karakteristike terapije pacijenta. Obrada rezultata
izvršena je primenom softvera SPSS (ver. 25). U istraživanju je učestvovalo 287 pacijenata,
prosečne starosti 72,2±5,8 godina (ukupan opseg 65-91). Prosečan broj lekova po pacijentu
iznosio je 7,6±2,2 (4-18), dok je prosečan broj indikacija iznosio 4,5±1,7 (1-11). Ukupna
zastupljenost benzodiazepina iznosila je 28,9%, od čega su dugodelujući bili primenjivani
kod 24.0%, a kratkodelujući kod 5,2% pacijenata. Najčešće primenjivan lek iz ove grupe bio
je bromazepam (17,1%), potom diazepam (7.0%), lorazepam (3,8%) i alprazolam (1,4%). U
grupi pacijenata starosti 65-69 godina prevalenca primene benzodiazepina iznosila je 29,3%,
70-74 godina 33,7%, 75-80 godina 23,3% i kod starijih od 80 godina 24.0%. Primena
benzodiazepina bila je statistički značajno češća kod pacijenata sa dijagnozom anksioznosti,
drugog mentalnog oboljenja, ali i primenom bisfosfonata, analgetika ili biljnog leka ekstrakta
lista Ginko biloba (p<0,05). Određena je visoka učestalost primene benzodiazepina kod
starijih pacijenata. Farmaceuti u javnim apotekama mogu imati značajnu ulogu u proceni i
minimizaciji rizika od neželjenog događaja, koji uključuju savetovanje pacijenata o prevenciji
padova, ali i mogućnostima postepene obustave ovih lekova kada ne postoji ubedljiva
indikacija za njihovu dugotrajnu primenu., The use of benzodiazepines in elderly patients is associated with the numerous adverse
outcomes, such as an increased risk of falls, fractures, health care costs, and even mortality.
The aim was to investigate the frequency of benzodiazepine use in patients aged ≥65 years,
and to explore the association of their use with patient characteristics. Demographic, clinical,
and therapy characteristics were collected prospectively in the community pharmacies. Data
analysis was performed using SPSS software (ver. 25). The study included 287 patients, with
a mean age of 72.2±5.8 years (total range 65-91), the average number of drugs 7.6±2.2 (4-
18), and the average number of indications 4.5±1.7 (1-11). The total prevalence of
benzodiazepine use was 28.9%, long-acting 24.0% and short-acting 5.2%. The most
commonly used was bromazepam (17.1%), followed by diazepam (7.0%), lorazepam (3.8%)
and alprazolam (1.4%). In the patients aged 65-69 years, the prevalence of benzodiazepine
use was 29.3%, 70-74 years 33.7%, 75-80 years 23.3% and in ≥80 years 24.0%. The use of
benzodiazepines was statistically significantly more common in patients diagnosed with
anxiety, other mental illness, but also with the comedication with bisphosphonates,
analgesics or herbal medicine Ginkgo biloba leaf extract (p<0.05). A high frequency of
benzodiazepine use was determined in elderly patients. Community pharmacists can play a
significant role in assessing and minimizing the risk of adverse events. Interventions may
include counseling on the prevention of falls, but also the possibility of drug discontinuation
when there is no convincing indication for their long-term use.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Učestalost primene benzodiazepina kod starijih pacijenata u primarnoj zdravstvenoj zaštiti, Frequency of benzodiazepine use in elderly primary care patients",
volume = "72",
number = "4 suplement",
pages = "S258-S259",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4386"
}

Kovačević, M., Jovanović, M., Ćulafić, M., Roganović, M., Vučićević, K., Vezmar-Kovačević, S.,& Miljković, B.. (2022). Učestalost primene benzodiazepina kod starijih pacijenata u primarnoj zdravstvenoj zaštiti. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S258-S259.
https://hdl.handle.net/21.15107/rcub_farfar_4386

Kovačević M, Jovanović M, Ćulafić M, Roganović M, Vučićević K, Vezmar-Kovačević S, Miljković B. Učestalost primene benzodiazepina kod starijih pacijenata u primarnoj zdravstvenoj zaštiti. in Arhiv za farmaciju. 2022;72(4 suplement):S258-S259.
https://hdl.handle.net/21.15107/rcub_farfar_4386 .

Kovačević, Milena, Jovanović, Marija, Ćulafić, Milica, Roganović, Maša, Vučićević, Katarina, Vezmar-Kovačević, Sandra, Miljković, Branislava, "Učestalost primene benzodiazepina kod starijih pacijenata u primarnoj zdravstvenoj zaštiti" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S258-S259,
https://hdl.handle.net/21.15107/rcub_farfar_4386 .

TY  - CONF
AU  - Ćatić-Đorđević, Aleksandra
AU  - Kovačević, Milena
AU  - Vezmar-Kovačević, Sandra
AU  - Stanković, Ljiljana
AU  - Petrović, Branko
AU  - Anđelković, Jasna
AU  - Milošević, Jelena
AU  - Nedeljković, Marina
AU  - Miljković, Branislava
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4463
C3  - FIP Seville 2022, 
80th FIP World Congress of Pharmacy
and Pharmaceutical Sciences
Seville, Spain, 18 to 22 September 2022, Abstract
T1  - Safe pharmacotherapy management of breastfeeding woman in community pharmacy- new pharmaceutical care service
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4463
ER  - 

@conference{
author = "Ćatić-Đorđević, Aleksandra and Kovačević, Milena and Vezmar-Kovačević, Sandra and Stanković, Ljiljana and Petrović, Branko and Anđelković, Jasna and Milošević, Jelena and Nedeljković, Marina and Miljković, Branislava",
year = "2022",
journal = "FIP Seville 2022, 
80th FIP World Congress of Pharmacy
and Pharmaceutical Sciences
Seville, Spain, 18 to 22 September 2022, Abstract",
title = "Safe pharmacotherapy management of breastfeeding woman in community pharmacy- new pharmaceutical care service",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4463"
}

Ćatić-Đorđević, A., Kovačević, M., Vezmar-Kovačević, S., Stanković, L., Petrović, B., Anđelković, J., Milošević, J., Nedeljković, M.,& Miljković, B.. (2022). Safe pharmacotherapy management of breastfeeding woman in community pharmacy- new pharmaceutical care service. in FIP Seville 2022, 
80th FIP World Congress of Pharmacy
and Pharmaceutical Sciences
Seville, Spain, 18 to 22 September 2022, Abstract.
https://hdl.handle.net/21.15107/rcub_farfar_4463

Ćatić-Đorđević A, Kovačević M, Vezmar-Kovačević S, Stanković L, Petrović B, Anđelković J, Milošević J, Nedeljković M, Miljković B. Safe pharmacotherapy management of breastfeeding woman in community pharmacy- new pharmaceutical care service. in FIP Seville 2022, 
80th FIP World Congress of Pharmacy
and Pharmaceutical Sciences
Seville, Spain, 18 to 22 September 2022, Abstract. 2022;.
https://hdl.handle.net/21.15107/rcub_farfar_4463 .

Ćatić-Đorđević, Aleksandra, Kovačević, Milena, Vezmar-Kovačević, Sandra, Stanković, Ljiljana, Petrović, Branko, Anđelković, Jasna, Milošević, Jelena, Nedeljković, Marina, Miljković, Branislava, "Safe pharmacotherapy management of breastfeeding woman in community pharmacy- new pharmaceutical care service" in FIP Seville 2022, 
80th FIP World Congress of Pharmacy
and Pharmaceutical Sciences
Seville, Spain, 18 to 22 September 2022, Abstract (2022),
https://hdl.handle.net/21.15107/rcub_farfar_4463 .

TY  - JOUR
AU  - Ćulafić, Milica
AU  - Kovačević, Milena
AU  - Jovanović, Marija
AU  - Roganović, Maša
AU  - Vezmar-Kovačević, Sandra
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4383
AB  - COPD is a chronic condition requiring care from a multidisciplinary team in which pharma-
cists play an important role. We aimed to evaluate the impact of structured pharmacist-patient counsel-
ing on patients’ knowledge, and attitudes about medicines and the impact of COPD on patients’ health
status. A prospective study was conducted in ten community pharmacies. Patients were counseled using
a detailed approach after completing validated questionnaires. The patients returned to a pharmacy for
a follow-up after three months. Four validated questionnaires have been used to assess different aspects
of patient’s knowledge about the disease, their attitudes about medicines, and the impact of the disease on
patients’ health status: COPD Assessment Test (CAT), Modified Medical Research Council Dyspnea Scale
(mMRC), Bristol COPD Knowledge Questionnaire (BCKQ), and The Beliefs about Medicines Question-
naire (BMQ). Pharmacists recruited 83 COPD patients, from which 73 patients attended a follow-up visit.
Before pharmacist intervention, the CAT median score was 20. After counseling, the CAT score decreased
to 18 (p < 0.05). The highest improvement in patient knowledge was observed for inhaled bronchodila-
tors (28.2%), vaccination (25.8%), oral steroids (24.4%), and smoking (24.2%). The median score for
necessity increased, whereas the harm and concern median scores considerably decreased (p < 0.05) after
counseling. The results showed significant improvements in all aspects covered throughout pharmacist-
patient counseling. Based on our results, the proactive role of the pharmacist in the care of COPD patients
may be beneficial to patients, physicians, and healthcare by improving care, and alleviating the strain on
overloaded doctors by containing the costs.
PB  - Polish Pharmaceutical Society
T2  - Acta Poloniae Pharmaceutica - Drug Research
T1  - Community pharmacist-driven interventions in COPD: improving knowledge, attitude and health status
VL  - 79
IS  - 5
SP  - 725
EP  - 734
DO  - 10.32383/appdr/155353
ER  - 

@article{
author = "Ćulafić, Milica and Kovačević, Milena and Jovanović, Marija and Roganović, Maša and Vezmar-Kovačević, Sandra and Vučićević, Katarina and Miljković, Branislava",
year = "2022",
abstract = "COPD is a chronic condition requiring care from a multidisciplinary team in which pharma-
cists play an important role. We aimed to evaluate the impact of structured pharmacist-patient counsel-
ing on patients’ knowledge, and attitudes about medicines and the impact of COPD on patients’ health
status. A prospective study was conducted in ten community pharmacies. Patients were counseled using
a detailed approach after completing validated questionnaires. The patients returned to a pharmacy for
a follow-up after three months. Four validated questionnaires have been used to assess different aspects
of patient’s knowledge about the disease, their attitudes about medicines, and the impact of the disease on
patients’ health status: COPD Assessment Test (CAT), Modified Medical Research Council Dyspnea Scale
(mMRC), Bristol COPD Knowledge Questionnaire (BCKQ), and The Beliefs about Medicines Question-
naire (BMQ). Pharmacists recruited 83 COPD patients, from which 73 patients attended a follow-up visit.
Before pharmacist intervention, the CAT median score was 20. After counseling, the CAT score decreased
to 18 (p < 0.05). The highest improvement in patient knowledge was observed for inhaled bronchodila-
tors (28.2%), vaccination (25.8%), oral steroids (24.4%), and smoking (24.2%). The median score for
necessity increased, whereas the harm and concern median scores considerably decreased (p < 0.05) after
counseling. The results showed significant improvements in all aspects covered throughout pharmacist-
patient counseling. Based on our results, the proactive role of the pharmacist in the care of COPD patients
may be beneficial to patients, physicians, and healthcare by improving care, and alleviating the strain on
overloaded doctors by containing the costs.",
publisher = "Polish Pharmaceutical Society",
journal = "Acta Poloniae Pharmaceutica - Drug Research",
title = "Community pharmacist-driven interventions in COPD: improving knowledge, attitude and health status",
volume = "79",
number = "5",
pages = "725-734",
doi = "10.32383/appdr/155353"
}

Ćulafić, M., Kovačević, M., Jovanović, M., Roganović, M., Vezmar-Kovačević, S., Vučićević, K.,& Miljković, B.. (2022). Community pharmacist-driven interventions in COPD: improving knowledge, attitude and health status. in Acta Poloniae Pharmaceutica - Drug Research
Polish Pharmaceutical Society., 79(5), 725-734.
https://doi.org/10.32383/appdr/155353

Ćulafić M, Kovačević M, Jovanović M, Roganović M, Vezmar-Kovačević S, Vučićević K, Miljković B. Community pharmacist-driven interventions in COPD: improving knowledge, attitude and health status. in Acta Poloniae Pharmaceutica - Drug Research. 2022;79(5):725-734.
doi:10.32383/appdr/155353 .

Ćulafić, Milica, Kovačević, Milena, Jovanović, Marija, Roganović, Maša, Vezmar-Kovačević, Sandra, Vučićević, Katarina, Miljković, Branislava, "Community pharmacist-driven interventions in COPD: improving knowledge, attitude and health status" in Acta Poloniae Pharmaceutica - Drug Research, 79, no. 5 (2022):725-734,
https://doi.org/10.32383/appdr/155353 . .

TY  - CONF
AU  - Ćulafić, Milica
AU  - Đorđević, J.
AU  - Stanković, Sanja
AU  - Štulić, Miloš
AU  - Pejić, Nina
AU  - Vezmar-Kovačević, Sandra
AU  - Oluić, Branislav
AU  - Miljković, Branislava
AU  - Ćulafić, Đorđe
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4337
PB  - Elsevier B.V.
C3  - Clinica Chimica Acta
T1  - Adverse drug reactions of tacrolimus after liver transplant - Our Experience
VL  - 530
IS  - Supplement 1
SP  - S448
EP  - S448
DO  - doi.org/10.1016/j.cca.2022.04.395
ER  - 

@conference{
author = "Ćulafić, Milica and Đorđević, J. and Stanković, Sanja and Štulić, Miloš and Pejić, Nina and Vezmar-Kovačević, Sandra and Oluić, Branislav and Miljković, Branislava and Ćulafić, Đorđe",
year = "2022",
publisher = "Elsevier B.V.",
journal = "Clinica Chimica Acta",
title = "Adverse drug reactions of tacrolimus after liver transplant - Our Experience",
volume = "530",
number = "Supplement 1",
pages = "S448-S448",
doi = "doi.org/10.1016/j.cca.2022.04.395"
}

Ćulafić, M., Đorđević, J., Stanković, S., Štulić, M., Pejić, N., Vezmar-Kovačević, S., Oluić, B., Miljković, B.,& Ćulafić, Đ.. (2022). Adverse drug reactions of tacrolimus after liver transplant - Our Experience. in Clinica Chimica Acta
Elsevier B.V.., 530(Supplement 1), S448-S448.
https://doi.org/doi.org/10.1016/j.cca.2022.04.395

Ćulafić M, Đorđević J, Stanković S, Štulić M, Pejić N, Vezmar-Kovačević S, Oluić B, Miljković B, Ćulafić Đ. Adverse drug reactions of tacrolimus after liver transplant - Our Experience. in Clinica Chimica Acta. 2022;530(Supplement 1):S448-S448.
doi:doi.org/10.1016/j.cca.2022.04.395 .

Ćulafić, Milica, Đorđević, J., Stanković, Sanja, Štulić, Miloš, Pejić, Nina, Vezmar-Kovačević, Sandra, Oluić, Branislav, Miljković, Branislava, Ćulafić, Đorđe, "Adverse drug reactions of tacrolimus after liver transplant - Our Experience" in Clinica Chimica Acta, 530, no. Supplement 1 (2022):S448-S448,
https://doi.org/doi.org/10.1016/j.cca.2022.04.395 . .

TY  - CONF
AU  - Kovačević, Milena
AU  - Vezmar-Kovačević, Sandra
AU  - Radovanović, Slavica
AU  - Stevanović, Predrag
AU  - Miljković, Branislava
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3826
AB  - Background Exposure to anticholinergic and sedative drugs have been associated with adverse health outcomes in the elderly population, which can be measured in an individual patient using Drug Burden Index (DBI). Higher DBI values were associated with poorer cognitive and physical performance, which may negatively influence cardiovascular disease (CVD) therapy outcomes.

Purpose The aim was to assess the anticholinergic and sedative drug prevalence and burden in CVD patients.

Method A retrospective observational study was conducted on the Cardiology ward of University Hospital Medical Center. Data were collected from medical records. DBI was used to calculate the exposure, based on the therapy used before the hospital admission. Descriptive and statistical analysis was performed using IBM SPSS® Statistics ver. 22.

Findings A total of 254 patients aged ≥65 were included in the analysis. Patients were comorbid (Charlson Comorbidity Index, mean ± S.D., 3.18 ± 1.63), with the average number of drugs above 6 (6.21 ± 2.78). Anticholinergic or sedative drugs were used by 23 (9.1%) patients, with identified 19 different drugs. The highest frequency was observed for doxazosin (6; 2.4%), sertraline (6; 2.4%), memantine (4; 1.6%), clonazepam (3; 1.2%) and diazepam (3; 1.2%). The majority of patients had only one drug (15; 5.9%), 2 patients (0.8%) used 2, 4 patients (1.6%) used 3, and 2 patients (0.8%) used 4 different drugs with anticholinergic or sedative effects. Patients who were exposed to those drugs had longer length of hospital stay (15.74 vs 9.41 days, p<0.05), and higher total number of drugs (7.61 vs 6.07, p<0.05). The average DBI value equalled 1.11 ± 0.74 (total range 0.33-2.60). DBI <1 was present in 13 (5.1%) patients, and higher DBI≥1 in 10 (4%) patients.

Conclusion The study revealed lower than expected exposure to anticholinergic or sedative drugs. The results could be seen as beneficial, as the minimization of anticholinergic burden in CVD patients is highly recommended.
PB  - Springer Nature
C3  - International Journal of Clinical Pharmacy, 12th PCNE working conference ‘Partnering for better patient outcomes: challenges and opportunities 3–6 February 2021, University of Basel, Switzerland (was held online)
T1  - Anticholinergic and sedative drug burden in elderly patients with cardiovascular diseases (oral presentation)
IS  - 459
DO  - 10.1007/s11096-021-01269-4
ER  - 

@conference{
author = "Kovačević, Milena and Vezmar-Kovačević, Sandra and Radovanović, Slavica and Stevanović, Predrag and Miljković, Branislava",
year = "2021",
abstract = "Background Exposure to anticholinergic and sedative drugs have been associated with adverse health outcomes in the elderly population, which can be measured in an individual patient using Drug Burden Index (DBI). Higher DBI values were associated with poorer cognitive and physical performance, which may negatively influence cardiovascular disease (CVD) therapy outcomes.

Purpose The aim was to assess the anticholinergic and sedative drug prevalence and burden in CVD patients.

Method A retrospective observational study was conducted on the Cardiology ward of University Hospital Medical Center. Data were collected from medical records. DBI was used to calculate the exposure, based on the therapy used before the hospital admission. Descriptive and statistical analysis was performed using IBM SPSS® Statistics ver. 22.

Findings A total of 254 patients aged ≥65 were included in the analysis. Patients were comorbid (Charlson Comorbidity Index, mean ± S.D., 3.18 ± 1.63), with the average number of drugs above 6 (6.21 ± 2.78). Anticholinergic or sedative drugs were used by 23 (9.1%) patients, with identified 19 different drugs. The highest frequency was observed for doxazosin (6; 2.4%), sertraline (6; 2.4%), memantine (4; 1.6%), clonazepam (3; 1.2%) and diazepam (3; 1.2%). The majority of patients had only one drug (15; 5.9%), 2 patients (0.8%) used 2, 4 patients (1.6%) used 3, and 2 patients (0.8%) used 4 different drugs with anticholinergic or sedative effects. Patients who were exposed to those drugs had longer length of hospital stay (15.74 vs 9.41 days, p<0.05), and higher total number of drugs (7.61 vs 6.07, p<0.05). The average DBI value equalled 1.11 ± 0.74 (total range 0.33-2.60). DBI <1 was present in 13 (5.1%) patients, and higher DBI≥1 in 10 (4%) patients.

Conclusion The study revealed lower than expected exposure to anticholinergic or sedative drugs. The results could be seen as beneficial, as the minimization of anticholinergic burden in CVD patients is highly recommended.",
publisher = "Springer Nature",
journal = "International Journal of Clinical Pharmacy, 12th PCNE working conference ‘Partnering for better patient outcomes: challenges and opportunities 3–6 February 2021, University of Basel, Switzerland (was held online)",
title = "Anticholinergic and sedative drug burden in elderly patients with cardiovascular diseases (oral presentation)",
number = "459",
doi = "10.1007/s11096-021-01269-4"
}

Kovačević, M., Vezmar-Kovačević, S., Radovanović, S., Stevanović, P.,& Miljković, B.. (2021). Anticholinergic and sedative drug burden in elderly patients with cardiovascular diseases (oral presentation). in International Journal of Clinical Pharmacy, 12th PCNE working conference ‘Partnering for better patient outcomes: challenges and opportunities 3–6 February 2021, University of Basel, Switzerland (was held online)
Springer Nature.(459).
https://doi.org/10.1007/s11096-021-01269-4

Kovačević M, Vezmar-Kovačević S, Radovanović S, Stevanović P, Miljković B. Anticholinergic and sedative drug burden in elderly patients with cardiovascular diseases (oral presentation). in International Journal of Clinical Pharmacy, 12th PCNE working conference ‘Partnering for better patient outcomes: challenges and opportunities 3–6 February 2021, University of Basel, Switzerland (was held online). 2021;(459).
doi:10.1007/s11096-021-01269-4 .

Kovačević, Milena, Vezmar-Kovačević, Sandra, Radovanović, Slavica, Stevanović, Predrag, Miljković, Branislava, "Anticholinergic and sedative drug burden in elderly patients with cardiovascular diseases (oral presentation)" in International Journal of Clinical Pharmacy, 12th PCNE working conference ‘Partnering for better patient outcomes: challenges and opportunities 3–6 February 2021, University of Basel, Switzerland (was held online), no. 459 (2021),
https://doi.org/10.1007/s11096-021-01269-4 . .